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Abstract 
Acetyl-CoA holds a prominent position as the common metabolic 
intermediate of glucose, amino acid and fatty acid oxidation. Because acetyl-CoA 
fuels the tricarboxylic acid (TCA) cycle which produces reducing equivalents that 
drive mitochondrial oxidative phosphorylation, understanding acetyl-CoA pool 
regulation becomes imperative to understanding mitochondrial energetics. 
Carnitine acetyltransferase (CrAT), a muscle-enriched mitochondrial enzyme, 
catalyzes the freely reversible conversion of acetyl-CoA to its membrane 
permeant carnitine ester, acetylcarnitine. Because CrAT has long been thought 
to regulate the acetyl-CoA metabolite pool, we investigated the role of CrAT in 
acetyl-CoA regulation. Although the biochemistry and enzymology of the CrAT 
reaction has been well studied, its physiological role remains unknown. 
Investigations herein suggest that CrAT-mediated maintenance of the 
mitochondrial acetyl-CoA pool is imperative for preservation of energy 
homeostasis. We provide compelling evidence that CrAT is critical for fine-tuning 
acetyl-CoA balance during the fasted to fed transition and during exercise. These 
studies suggest that compromised CrAT activity results in derangements in 
mitochondrial homeostasis. 
In chapter 3, we examined the effects of obesity and lipid exposure on CrAT 
activity. Recent studies have shown that acetyl-CoA-mediated inhibition of 
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pyruvate dehydrogenase (PDH), the committed step in glucose oxidation, is 
modulated by the CrAT enzyme. Because PDH and glucose oxidation are 
negatively regulated by high fat feeding and obesity, we reasoned that nutritional 
conditions that promote lipid availability and fat oxidation might likewise 
compromise CrAT activity. We report an accumulation of long chain 
acylcarnitines and acyl-CoAs but a decline in the acetylcarnitine/acetyl-CoA ratio 
in obese and diabetic rodents. This reduction in the skeletal muscle 
acetylcarnitine/acetyl-CoA ratio was accompanied by a decrease in CrAT specific 
activity, despite increased protein abundance. Exposure to long chain acyl-CoAs 
in vitro demonstrated that palmitoyl-CoA acts as a mixed model inhibitor of CrAT. 
Furthermore, primary human skeletal muscle myocytes exposed to fatty acid and 
or CPT1b overexpression had elevated long chain acylcarnitines but decreased 
production and efflux of CrAT-derived short chain acylcarnitines. These data 
suggest that exposure to fatty acids in obesity and diabetes can counter-regulate 
the CrAT enzyme leading to decreased activity.  
Alternatively, chapter 4 addresses the importance of acetyl-CoA buffering 
during exercise and suggests that a deficit in CrAT activity leads to fatigue. 
Because CrAT is highly expressed in tissues specifically designed for work and 
because acetylcarnitine, the primary product of the CrAT reaction, is increased 
during contraction, we reasoned that CrAT could play an important role in 
exercise. To investigate this possibility, we employed exercise intervention and 
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ex-vivo analysis on a genetically novel mouse model of skeletal muscle CrAT 
deficiency (CrATSM-/-). Though resting acetyl-CoA levels were elevated in CrATSM-
/- mice, these levels dropped significantly after intense exercise while 
acetylcarnitine content followed the opposite pattern. This contraction-induced 
acetyl-CoA deficit in CrATSM-/- mice was coupled with compromised performance 
and diminished whole body glucose oxidation during high intensity exercise. 
These results imply that working muscles clear and consume acetylcarnitine in 
order to maintain acetyl-CoA buffering during exercise. Importantly, provision of 
acetylcarnitine enhanced force generation, delayed fatigue and improved 
mitochondrial energetics in muscles from CrATfl/fl controls but not CrATSM-/- 
littermates, emphasizing the importance of acetyl-CoA pool maintenance. In 
aggregate, these data demonstrate a critical role for CrAT-mediated acetyl-CoA 
buffering in exercise tolerance and suggest its involvement in energy metabolism 
during skeletal muscle contraction and fatigue. These findings could have 
important clinical implications for individuals with muscle weakness and fatigue 
due to multiple conditions, such as peripheral vascular or cardiometabolic 
disease.  
In summary, data herein emphasize the role of CrAT in regulation of the 
mitochondrial acetyl-CoA pool. We demonstrate that CrAT is critical for fine-
tuning acetyl-CoA balance both during the fasted to fed transition and during 
exercise. These data suggest that a deficit in CrAT activity leads to glucose 
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intolerance and exercise fatigue. We examine these studies and suggest future 
areas of study.  
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1 Introduction  
1.1 Acetyl-CoA: The Universal Substrate 
Acetyl-CoA holds a predominant position as a key substrate and 
regulatory metabolite in multiple enzymatic processes. Multiple cellular pools of 
acetyl-CoA exist. Mitochondrial acetyl-CoA, the two carbon metabolic 
intermediate of glucose, amino acid and fatty acid oxidation, is a primary 
substrate of the tricarboxylic acid cycle (TCA cycle). As such, the oxidation of 
acetyl-CoA fuels the production of reducing equivalents which are required for 
ATP generation. Alternatively, cytosolic acetyl-CoA acts as a building block for de 
novo fatty acid synthesis and elongation. When citrate synthesis exceeds TCA 
cycle flux, the resulting buildup of mitochondrial citrate can be exported to the 
cytosol via the citrate carrier. Citrate is then catabolized to oxaloacetate and 
acetyl-CoA by citrate lysase and may be utilized for lipogenesis following 
carboxylation to malonyl-CoA. Therefore, given this dual role as an oxidizable 
substrate and building block, acetyl-CoA is widely recognized as a universal 
substrate for both catabolic and anabolic processes. 
Acetyl-CoA has a well established role in enzymatic regulation. 
Mitochondrial acetyl-CoA is an allosteric inhibitor of pyruvate dehydrogenase 
(PDH), the enzyme complex that couples glycolysis to glucose oxidation.  
Moreover, acetyl-CoA has been shown to stimulate the activity of PDH kinases, 
which phosphorylate and inhibit PDH (Sugden and Holness 2006). In addition to 
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its role as a regulator of PDH activity, acetyl-CoA provides the substrate for 
acetylation of several key metabolic enzymes. Lysine acetylation, a reversible 
post-translational modification, has become increasingly recognized as a 
regulator of enzymatic activity. Supporting this hypothesis, an estimated 35% of 
mitochondrial proteins have been shown to be acetylated, the majority of which 
are involved in energy metabolism (Anderson and Hirschey 2012). Moreover, 
greater than 50% of these proteins are involved in glucose, fatty acid, and amino 
acid oxidation as well as the TCA cycle and oxidative phosphorylation (Anderson 
and Hirschey 2012), highlighting the potential importance of mitochondrial 
acetylation status on fuel metabolism. In aggregate, these data implicate acetyl-
CoA as a critical player in metabolism. 
1.2 Carnitine Trafficking of Acetyl Groups 
Because acetyl-CoA and other acyl-CoA precursors cannot cross 
mitochondrial membranes, conversion of CoA metabolites to their respective 
carnitine esters is important for cellular and inter-tissue carbon trafficking. Muscle 
acylcarnitines are produced by several acyltransferase enzymes responsible for 
the interconversion of acyl-CoAs and acylcarnitine metabolites. The carnitine 
palmitoyltransferase (CPT) enzymes have specificity for long chain acyl-CoAs, 
while carnitine octanoyltransferase (CrOT) is principally a medium-chain 
acyltransferase. Alternatively, carnitine acetyltransferase (CrAT) has been shown 
to act primarily on short-chain acyl-CoAs. Acyltransferase enzymes differ from 
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one another primarily in the acyl-CoA binding pocket, with minor amino acid 
alterations dramatically changing substrate chain length specificity (Cordente et 
al. 2006, Cordente et al. 2004).  
As a principal substrate of the acyltransferase enzymes, carnitine is best 
known for its role in shuttling long chain acyl-CoAs into the mitochondria for β-
oxidation. Oxidation of acyl-CoAs is initiated by CPT1, which catalyzes the 
production of acylcarnitine and yields free CoA. Carnitine acylcarnitine 
translocase (CACT) then transports the acylcarnitine across the mitochondrial 
membrane, where carnitine palmitoyltransferase 2 (CPT2) converts it back into 
acyl-CoA utilizing an intramitochondrial pool of free CoA. Long chain acyl-CoAs 
are then further metabolized through mitochondrial β-oxidation (figure 1).  
Notably however, in addition to its role in lipid oxidation, carnitine plays 
another comparatively understudied role in mitochondrial efflux of excess carbon 
fuels. The importance of this mechanism has been demonstrated in recent 
studies linking carnitine availability and glucose metabolism. These studies 
observed an improvement in whole body glucose tolerance in obese and diabetic 
rats after carnitine supplementation, an intervention that also caused a robust 
elevation of acetylcarnitine in both the plasma and urine (Noland et al. 2009). 
Because these studies and others have shown that perturbations in the carnitne 
pool may contribute to glucose intolerance (Noland et al. 2009, Powers et al. 
2007), understanding the intricacies of carnitine homeostasis becomes important 
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in the understanding of mitochondrial metabolism. Carnitine availability is 
regulated at multiple levels, such as intestinal absorption, renal reabsorption, 
dietary intake, and endogenous biosynthesis (Steiber et al. 2004). Carnitine 
content is highest in foods from animal sources, such as red meat. Approximately 
75% of total body carnitine comes from the diet in omnivorous humans, while 
vegetarians meet the majority of their carnitine needs via de novo biosynthesis 
(Steiber et al. 2004). Evidence suggests that carnitine synthesis can be 
compromised by depletion of essential co-factors in carnitine biosynthesis, such 
as iron, vitamin C, and α-ketoglutarate (Citak et al. 2006, Okamoto et al. 2006, 
Otsuka et al. 1999). Recent studies have additionally determined a regulatory 
role for PPARα, a fatty acid-sensing nuclear receptor and regulator of lipid 
metabolism, in both carnitine synthesis and transport (van Vlies et al. 2007).  
Once carnitine becomes available, it is transported into circulation via the 
organic cation family of transporters (OCT), which regulates both transport into 
and uptake from the circulation. OCTN2 is the primary carnitine transporter, 
located in the heart, skeletal muscle, kidney, placenta, small intestine and brain. 
Sodium-dependent transport of carnitine is achieved through OCTN2 with an 
apparent Km of 4.3 µM (Tamai et al. 1998). Interestingly, OCTN2 is also highly 
active in the transport of acetylcarnitine, with a Km of 8.5 µM (Ohashi et al. 
1999). In aggregate, the carnitine pool is regulated at multiple levels including 
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intake, transport and synthesis. Recent evidence linking carnitine homeostasis to 
obesity and diabetes will be examined in future sections. 
 
Figure 1: The Role of Carnitine and CrAT in Regulating Mitochondrial 
Energetics.  
Long chain acyl-CoA must first be converted to its carnitine counterpart before transversing the 
mitochondrial membrane via CPT1 and CACT. CPT2 then regenerates the acyl-CoA within the 
mitochondria for entry into β-oxidation. Each successive cycle in β-oxidation produces a two 
carbon acetyl-CoA. Acetyl-CoA, also produced via glycolysis through PDH, can then enter the 
TCA cycle for further catabolism. CrAT, a matrix protein, converts acetyl-CoA into acetylcarnitine, 
which can efflux from the mitochondria, thereby relieving PDH inhibition should acetyl-CoA 
production exceed consumption.  
 
1.3 Carnitine Acetyltransferase 
Due to its ability to channel acetyl-CoA between the mitochondrial and 
cytosolic compartments, CrAT has long been thought to act in a buffering 
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capacity, freeing CoA for continued oxidative reactions through the generation of 
acylcarnitines which exit the mitochondria, efflux from the cellular compartments 
and enter the circulation (Brass et al. 1980, Carter et al. 1981, Brookelman et al. 
1978). Because acetyl-CoA makes up greater than 90% of the total acyl-CoA 
pool, and because recent studies demonstrated the importance of acetylcarnitine 
efflux in obesity and diabetes, we examined the literature describing the CrAT 
enzyme.  
Though the physiological role of CrAT remains uncertain, much is known 
about the biochemistry and enzymology of the enzyme. CrAT is present in both 
the mitochondrial matrix and peroxisomes. Peroxisomal CrAT is thought to be 
essential in allowing efflux of chain-shortened intermediates derived from very 
long-chain fatty acid catabolism from the peroxisomes to the mitochondria for 
further oxidation (Vanhove et al. 1991). Peroxisomal and mitochondrial CrAT are 
both transcribed by a single gene mapped to chromosome 9q34.1 (Corti et al. 
1994, Corti et al. 1994b). It was found that the mitochondrial form of CrAT 
contains both peroxisomal and mitochondrial targeting sequences within the C- 
and N- terminal regions and that cleavage of the mitochondrial targeting 
sequence was required for peroxisomal targeting (Corti et al. 1994). This 
suggests that when present, the mitochondrial targeting sequence overrides 
peroxisomal targeting.  
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CrAT has been shown to be most abundant in skeletal muscle and heart, 
where it is primarily active in the mitochondria. CrAT has also been shown to be 
present in kidney and brain with low levels of enzyme in liver (Noland et al. 
2009). Acetyl-CoA is largely consumed by the TCA cycle in muscle, while liver 
primarily utilizes acetyl-CoA for ketones and lipid synthesis.  Therefore, though 
present in liver peroxisomes, CrAT is largely absent from liver mitochondria, 
likely because the presence of mitochondrial CrAT would disrupt ketone and lipid 
synthesis. Though little is known about the role of neuronal CrAT, in the two 
cases of human CrAT deficiency reported, both patients died in infancy with 
severe muscle derangements and neuronal defects (Melegh et al. 1999,  
DiDonato et al. 1979), suggesting a critical role for CrAT in muscle and brain 
metabolism.  
Structural and functional data indicate that CrAT operates with a random 
bi-bi mechanism, meaning that the binding of two substrates yields two distinct 
products with random binding order (Colucci and Gandour 1987). Previous 
studies concluded that short-chain acyl-CoAs are preferred substrates for the 
CrAT reaction. Substrate specificity has been determined in purified heart CrAT 
(Huckle and Tamblyn 1983, Fritz et al. 1963), purified bovine sperm CrAT 
(Huckle and Tamblyn 1983), purified pigeon CrAT (Chase et al. 1967, Chase and 
Tubbs 1966), and more recently in rat CrAT overexpressed in yeast cells 
(Cordente et al. 2004). Though propionyl-CoA (three carbon acyl-CoA) and in 
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some models butyryl-CoA (four carbon acyl-CoA) are better substrates for the 
CrAT enzyme, acetyl-CoA is by far the most abundant acyl-CoA. Therefore, 
CrAT is best known for its role in regulating acetyl-CoA levels within the 
mitochondria.  
Though substrate specificity has been well established, CrAT enzyme 
regulation is poorly understood. CrAT catalyzes the reversible reaction between 
short chain acyl-CoA and acylcarnitine with an equilibrium constant of 1.5–1.8 
(Farrell et al. 1984, Pieklik and Guynn 1975). Therefore, enzyme activity has long 
been thought to be regulated by substrate/product concentrations within the 
mitochondrial matrix. Early studies demonstrated CrAT activity can be 
antagonized by long chain acyl-CoAs, though the relevance of this inhibition 
remains unclear and will be discussed in Chapter 3 (Huckle et al. 1983, Mittal et 
al. 1980, Chase et al. 1967). Both Mittal et al. (1980) and Chase et al. (1967) 
concluded that palmitoyl-CoA interacts with a hydrophobic region on CrAT that 
hinders carnitine binding in a reversible manner. Chapter 3 will discuss the 
possible acylation of the CrAT enzyme and its implications for mitochondrial fuel 
utilization.  In aggregate, though much is known about the enzymology and 
biochemistry of the CrAT enzyme, its physiologic role in remains unknown. 
Therefore, we examine its role in obesity and diabetes in the following section. 
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1.4 Acetyl Group Imbalance in Insulin Resistance and Diabetes 
Consumption of highly processed carbohydrate and fat-rich convenience 
food coupled with decreased physical activity has made obesity a global health 
concern. In the US alone, well over one third of the adult population is considered 
obese (Flegal 2012). Obesity is a primary physiologic component in what is 
known as the “metabolic syndrome,” a set of risk factors highly correlated with 
type 2 diabetes (Chan et al. 1994), and cardiovascular disease (Shan et al. 
2009).  
Insulin resistance, a hallmark of type 2 diabetes, is the failure of metabolic 
tissue to appropriately respond to the hormone insulin. The insulin-mediated 
capacity to clear blood glucose via skeletal muscle uptake and to limit glucose 
production by the liver is diminished, leading to compensatory insulin secretion 
and pancreatic β-­‐cell expansion. This adaptation, in part, explains the abundance 
of individuals who are obese but not yet diabetic (Chan et al. 1994). The onset of 
type 2 diabetes results from the eventual impairment of β-­‐cell function, resulting 
in an inability to produce insulin and maintain euglycemia (Pfeifer et al. 1981). 
Therefore, research targeting insulin resistance in the pre-diabetic state has 
become increasingly important.  
One characteristic of the insulin resistant state is the inability of skeletal 
muscle to properly adjust to nutritional cues. This “metabolic inflexibility” refers to 
the apparent failure of insulin resistant animals to appropriately switch between 
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oxidation of fatty acid and glucose substrates (Kelley et al. 1999). In the fed 
state, healthy individuals experience a rise in glucose oxidation, whereas in the 
fasted state, lipids become the primary fuel. This concept, coined the “glucose-
fatty acid cycle,” was first postulated by Randle et al. in 1963 and proposes that 
products of lipid oxidation such as acetyl-CoA, NADH and ATP suppress glucose 
metabolism via allosteric inhibition of PDH.  More recent work demonstrated that 
the same set of allosteric inhibitors activate a family of PDH kinases, which 
phosphorylate and inhibit PDH (Sugden and Holness 2003). Randle additionally 
proposed a lipid product-mediated inhibition of phosphofructokinase-1 and 
hexokinase in the cytosol.  
However, research interest has since shifted away from the Randle 
hypothesis. Recent studies have shown that decreased skeletal muscle glucose, 
the substrate of hexokinase, persists in diabetic subjects, suggesting that 
inhibition of hexokinase and phosphofructokinase does not drive insulin 
resistance (Cline et al. 1994). Therefore, research targeting insulin signaling and 
glucose uptake has gained momentum. Glucose uptake is driven by expansion of 
cell membrane GLUT4, which is set in motion by insulin signaling. This cascade 
is initiated when insulin binding results in auto-activation of the insulin receptor 
followed by tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), 
leading to translocation of GLUT4-containing vesicles to the sarcolemma. 
Persistent serine phosphorylation by serine kinases, such as protein kinase C 
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(PKC) and c-jun N-terminal kinase (JNK), negatively regulate both the insulin 
receptor and IRS-1 in the insulin resistant state (Morino et al. 2006). Bioactive 
lipid signaling molecules have been implicated in this role. Diacylglycerols, long 
chain acyl-CoAs and ceramides activate these serine kinases along with a series 
of proinflammatory signals (Kim et al. 2007, Senn 2006, Shi et al. 2006), resulting 
in decreased insulin signal transmission and glucose uptake (Hirosumi et al. 
2002 and Shulman et al. 2000). In aggregate, these studies and others led to a 
model in which muscle mitochondria diverts fatty acids away from oxidation and 
toward the formation of toxic lipid metabolites which antagonize insulin signaling.  
1.5 Metabolic Profiling Provides New Insights into the Randle 
Cycle 
Several lines of evidence argue against ectopic fat accumulation as a 
primary cause of insulin resistance. For example, an accumulation of 
intramuscular fatty acids is present in insulin sensitive athletes (Goodpaster and 
Kelley 2002). Moreover, exercise intervention improved insulin sensitivity in type 
2 diabetic patients without a subsequent reduction in long chain acyl-CoA or 
diacylglycerol levels (Bruce et al. 2004) thereby calling into question the idea that 
mitochondrial dysfunction is a core cause of fat accumulation and muscle insulin 
resistance.  
Recently studies have refocused attention on the link between 
mitochondrial energetics and insulin signaling with the observation that lipid-
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induced derangements in substrate switching occurred within isolated 
mitochondria (Noland et al. 2009, Koves et al. 2008). In support of this model, 
use of targeted mass spectrometry-based metabolic profiling suggested that 
excessive β-oxidation might be a root cause of insulin resistance. These studies 
demonstrated that insulin resistant skeletal muscle was marked by excessive 
entry into β-oxidation leading to elevated incomplete oxidation of lipid fuels and 
coincident lowering of tricarboxylic acid cycle (TCA cycle) intermediates (Koves 
et al. 2008). Importantly, incomplete oxidation, or the accumulation of medium 
and short chain acylcarnitines, has become recognized as a signature of obese 
and diabetic muscle (Boyle et al. 2011, Kovalik et al. 2011, Thyfault et al. 2010, 
Noland et al. 2009, Koves et al. 2008).  
These data linking excessive carbon load to insulin resistance are in line 
with emerging evidence that muscle glucose intolerance is driven by 
mitochondrial stress. Indeed, recent studies suggest that an excess in carbon 
load in the absence of ATP demand leads to persistent pressure on the electron 
transport chain, yielding reactive oxygen species (ROS) production and disrupted 
redox balance (Bloch-Damti and Bashan 2005, Evans et al. 2005). ROS 
generation is thought to primarily occur within the electron transport chain (ETC) 
and has been demonstrated to principally result from excessive fatty acid-
supported respiration (Anderson et al. 2009). Mitochondrial ATP generation relies 
on the ETC using both an electron donor coming from fuel, and oxygen, the 
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electron acceptor.  Electron donors in the form of the reducing equivalents NADH 
and FADH2 drive the electron transport chain. Both β-oxidation and the TCA 
cycle produce FADH2 which donates electrons to the electron-transfer 
flavoprotein (ETF) and into to the ETC via the ubiquinone (Q) cycle. Likewise, 
NADH, produced by β-oxidation, PDH and multiple enzymes in the TCA cycle, 
enters the ETC at complex I and provides electrons into the Q cycle. ROS 
production is high when ATP demand is exceeded by electron flux into the ETC. 
This causes heightened backpressure on complex I, resulting in increased 
electron leak and ROS production (reviewed in Fisher-Wellman and Neufer 2012, 
Muoio and Neufer 2012). ROS generation has been shown to activate multiple 
serine kinases and transcription factors implicated in aberrant insulin signaling 
(Bloch-Damti and Bashan 2005, Chakraborti and Chakraborti 1998), thereby 
highlighting the association between ROS production and glucose intolerance. 
Further linking acetyl group accumulation and insulin signaling is the 
finding that overnutrition and insulin resistance lead to changes in the 
mitochondrial acetylation state (Hirschey et al. 2009, Huang et al. 2010). An 
estimated 35% of mitochondrial proteins have been shown to be acetylated, with 
acetylated proteins present in every major pathway in mitochondrial metabolism 
(Anderson and Hirschey 2012). Three mitochondrial sirtuin deacetylase enzymes 
have been identified to be important for regulation of the mitochondrial 
acetylation state. These will be discussed in more detail in the future directions 
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section. The primary deacetylase, SIRT3, has been shown to act on long chain 
acyl-CoA dehydrogenase (LCAD) and superoxide dismutase (SOD), 
deacetylating and increasing enzyme activity (Hirschey et al. 2010, Qui et al. 
2010). Interestingly, chronic nutrient overload led to decreased SIRT3 protein 
and mRNA in both liver (Hirschey et al. 2011, Bao et al. 2010) and skeletal 
muscle (Jing et al. 2011), resulting in mitochondrial hyperacetylation. These data 
suggest a link between the mitochondrial acetylation and glucose intolerance. In 
support of this hypothesis, SIRT3 knockout mice developed insulin resistance 
with aging (Hirschey et al. 2010, Jing et al. 2011, Qui et al. 2010). These data 
support the idea that nutrient-induced acetyl-CoA accumulation might play a 
causal role in the metabolic syndrome.  
In aggregate, caloric excess results in the production of potentially harmful 
intermediates which inhibit PDH, increase the mitochondrial acetylation state and 
overwhelm the ETC, producing ROS. These studies support the idea that 
mitochondrial stress brought on by excess carbon load results in derangements 
in glucose metabolism. Therefore, efflux of these metabolite intermediates out of 
the mitochondria could provide a “safety valve”, critical in the prevention of 
nutrient-induced mitochondrial stress.  
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1.6 Studies in CrAT Knockout Mice Support the Mitochondrial 
Stress Theory 
Because previous studies suggested that CrAT-mediated acetyl-CoA 
regulation might play a role in defending whole body glucose homeostasis 
(Noland et al. 2009), we used recombinant adenovirus manipulations of the CrAT 
protein in primary human skeletal muscle myocytes to examine the effect of CrAT 
activity on fuel metabolism. CrAT knockdown resulted in elevated fatty acid 
oxidation, while glucose uptake was diminished (Figure 2a). Moreover, 
overexpression of CrAT resulted in decreased fatty acid oxidation (Muoio et al. 
2012), and increased glucose uptake (Noland et al. 2009; Figure 2b) in primary 
human skeletal muscle cells. These data highlight the importance of CrAT activity 
in glucose metabolism. 
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Figure 2: CrAT Counterregulates Glucose and Fatty Acid Metabolism in 
Primary Human Skeletal Myocytes 
Treatment of primary human skeletal myocytes with rAD-shCrAT increased oxidation of 100 µM 
[1-14C]oleate to CO2 and decreased uptake of [3H]-2-deoxy-glucose (A), while overexpression of 
CrAT using rAD-CrAT decreased oxidation of 100 µM [1-14C]oleate to CO2 and increased uptake 
of [3H]-2-deoxy-glucose (B).  
 
 
In order to assess the role of CrAT in whole body fuel metabolism, we 
generated a muscle specific CrAT knock out mouse model. CrAT deficiency 
resulted in reduced muscle acetylcarnitine content, suggestive of an 
accumulation in mitochondrial acetyl-CoA. These derangements in CrAT-
mediated acetylcarnitine efflux were coupled with an insulin resistance 
phenotype and an inability to appropriately transition from fatty acid to pyruvate 
oxidation (Figure 3).  
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Figure 3: CrAT Deficiency Affects Whole Body and Mitochondrial 
Homeostasis 
CrAT muscle specific knockout mice (CrATM-/-) and control littermates (CrATfl/fl) were used to 
perform glucose tolerance tests after a low fat control diet (A). Isolated gastrocnemius muscle 
mitochondria were used to assess the dose-dependent pyruvate inhibition of fatty acid oxidation 
using 300 µM [1-14C]palmitate. Results were normalized to basal oxidation rates and IC50 values 
were calculated for the inhibitory effect of pyruvate on palmitate oxidation. 
  
Because acetyl-CoA is a potent inhibitor of PDH activity, we considered the idea 
that CrAT-mediated acetyl-CoA regulation could become imperative for PDH 
activity and glucose oxidation. As discussed previously, studies from Noland et 
al. 2009 supported this model, demonstrating that genetic and nutritional 
manipulations that enhance or diminish forward flux through the CrAT reaction 
resulted in corresponding changes in PDH activity and glucose disposal. In 
further support of this hypothesis, deletion of CrAT resulted in complete loss of 
carnitine-stimulated PDH activity in skeletal muscle mitochondria (Figure 4).  
These data suggest that CrAT-mediated acetyl-CoA regulation may be 
modulating PDH activity to increase glucose metabolism. 
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Figure 4: CrAT Regulates PDH Activity 
PDH activity was determined by measuring 14CO2 produced from 1 mM [1-14C]pyruvate ± 5 mM 
carnitine in isolated gastrocnemius muscle mitochondria from CrATM-/- and CrATfl/fl littermates.  
 
To further implicate a role for CrAT in combating nutrient stress, age 
matched human subjects with modestly elevated blood glucose underwent six 
months of carnitine supplementation (Noland et al. 2009). Importantly, carnitine 
permitted efflux of excess mitochondrial acetyl-CoA and enhanced insulin action. 
PDH activity and circulating acetylcarnitine were elevated while blood glucose 
and insulin were normalized. In aggregate, these data suggest that CrAT-
mediated acetyl-CoA regulation combats nutrient-induced mitochondrial stress 
and may serve as a therapeutically relevant target of metabolic inflexibility.  
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1.7 Acetyl-CoA Buffering in Exercise 
In addition to nutritional stress, exercise represents another physiological 
condition that causes dramatic swings in acetyl-CoA production and 
consumption. Rapid adjustments in the rate of mitochondrial ATP production 
depend on availability of oxygen as the final electron acceptor and a steady 
supply of electron donors. Acetyl-CoA is the primary substrate of the TCA cycle 
which supplies reducing equivalents as electron donors to the electron transport 
chain. Therefore, a deficit in acetyl-CoA supply would be predicted to limit the 
rate of oxidative ATP production.  
Two classifications of ATP production exist in exercise, aerobic or oxygen-
dependent and anaerobic or oxygen independent ATP production. During 
exercise, the majority of ATP is delivered to myosin ATPases, which consume 
ATP to facilitate contraction via power strokes involving actin and myosin. 
However, at rest, enough ATP exists to facilitate only a few seconds of 
contraction if not replenished (Hargreaves and Spriet 2006). Therefore, skeletal 
muscle production of ATP must match energy demand. While anaerobic ATP 
production provides an elevated rate of ATP compared to aerobic production, (up 
to 6 times faster), it is not sustainable. Additionally, accumulation of the lactate 
by-product of anaerobic glycolysis decreases muscle pH, thereby inhibiting 
enzymes in glycolysis and contributing to muscle cramping (Hargreaves and 
Spriet 2006). Therefore, aerobic ATP generation is the preferred form of energy 
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production for most exercise states. However, aerobic ATP generation cannot 
account for rapid fluctuations in ATP demand. 
Anaerobic ATP production predominantly occurs in type II muscle fibers 
which can be further subdivided into type IIA, or fast oxidative and type IIB or fast 
glycolytic fibers. The majority of anaerobic ATP generation comes from 
glycolysis, a cytosolic pathway ending in lactate production. Regulation of 
glycolysis is achieved primarily through phosphofructokinase activity, the kinase 
responsible for catalyzing the major regulated step in glycolysis. Accumulation of 
ADP and AMP activate this enzyme, stimulating glycolysis, while ATP is 
inhibitory. Provision of glucose for glycolysis is achieved through potent 
stimulation of glucose uptake into the muscle as well as elevations in glycogen 
utilization occurring during exercise. If blood glucose concentrations are 
maintained during contraction, glucose uptake continues to increase (Angus et 
al. 2002). However, if blood glucose is not maintained, glucose uptake peaks and 
begins to decline as levels become limiting (Katz et al. 1991, Ahlborg and Felig, 
1982, Ahlborg et al. 1974). Therefore, glycogen stores become essential for 
maintenance of glycolysis. Glycogen utilization, also stimulated by contraction, is 
at an energetic advantage, yielding three ATP per glucosyl group compared to 
the two ATP per glucose molecule. The importance of both blood glucose and 
glycogen in supplying ATP is emphasized by observations that fatigue 
associated with prolonged strenuous exercise is associated with glycogen 
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depletion and/or hypoglycemia (Coggan and Coyle 1987, Coyle et al. 1986, 
Coyle et al. 1983, Hermansen et al. 1967, McConell et al. 1999). However, 
anaerobic ATP can be generated from non-glycolysis sources.  
In extreme exercise, a small amount of ATP generation can come from the 
adenylate kinase reaction, which transfers a high energy phosphate from ADP to 
produce ATP and AMP. AMP is then degraded to IMP in order to keep the 
adenylate kinase reaction favoring the production of ATP. ATP can additionally 
be derived from the phosphocreatine (PCr) reaction wherein the conversion of 
PCr and ADP to creatine and ATP is catalyzed by creatine kinase. Though 
resting stores of PCr can serve as a rapid source of ATP generation, contraction 
cannot be sustained for longer than a few seconds using this fuel source alone 
(Hargreaves and Spriet 2006). 
In addition to its role in buffering changes in ATP demand, the creatine 
kinase reaction is critical for the rapid and efficient trafficking of ATP from its 
production site in the mitochondria to ATPase in the myofibrils during work. It has 
been estimated that as much as 80% of ATP transfer from the mitochondria to 
cytoplasm occurs through creatine kinase-dependent cycling (Aliev et al. 2011, 
Seppet et al. 2001, Guzun et al. 2012). Mitochondrial, cytosolic and myofibril 
creatine kinase isoforms couple ATP trafficking to contractile machinery. In 
support of this model, sensitivity to ADP in skeletal muscle fiber bundles was 
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greatest when both contractile signals and maximal creatine kinase activity were 
present (Perry et al. 2012).  
Anaerobic ATP production becomes vital during rapid changes in ATP 
demand and at the onset of exercise. A lag in oxygen-dependent provision of 
energy has been observed during initiation of exercise. This phenomenon, called 
the oxygen deficit, has been described using measurements in VO2 kinetics 
during contraction to reveal a disconnect between oxygen uptake and ATP 
demand during the transition from low to high workloads (Figure 5; adapted from 
Hargreaves and Spriet 2006). Two theories have been proposed to account for 
this lag in oxygen-dependent ATP generation. The first suggests a limitation in 
oxygen delivery to ETC, while the second proposes a deficit in acetyl group 
availability, also referred to as metabolic inertia.  Acetyl-CoA, the common 
metabolic intermediate of glucose, amino acid and fatty acid catabolism, fuels 
TCA cycle production of reducing equivalents. Because these reducing 
equivalents drive oxidative phosphorylation, a deficit in acetyl group production 
has been suggested to limit ATP generation. In support of this hypothesis, recent 
work demonstrated that expansion of the acetyl-CoA pool improved exercise 
performance (Howlett 1999, Timmons 1998, Timmons 1996), linking acetyl-CoA 
buffering to contractile capacity. In chapter 4 we examine the metabolic inertia 
theory by testing the role of CrAT-mediated skeletal muscle uptake and/or 
production of acetyl groups during exercise.  
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Figure 5: The Oxygen Deficit 
Diagram representing the lag in oxygen-dependent ATP production at the onset of exercise. 
Anaerobic ATP production is necessary to meet the energy requirements during this period.   
  
1.8 Project Goals 
The studies presented herein were designed to address the physiologic 
significance of CrAT-mediated acetyl-CoA buffering. These data demonstrate the 
critical role of CrAT in fine tuning the acetyl-CoA balance and suggest that 
absence of the CrAT enzyme results in glucose intolerance and fatigue. Chapter 
3 discusses the involvement of CrAT-mediated acetyl-CoA regulation in glucose 
homeostasis. Alternatively, work discussed in Chapter 4 highlights the essential 
role of acetyl-CoA buffering in exercise capacity and fatigue. These data address 
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the significance of acetyl-CoA regulation in multiple scenarios and suggest its 
therapeutic potential. 
Because acetyl-CoA regulation has been shown to play a role in glucose 
metabolism and metabolic flexibility (Noland et al. 2009), and because CrAT 
regulates this metabolite pool, understanding the regulation of this enzyme may 
be critical to our understanding of metabolic disease. Though studies focused on 
discerning CrAT enzyme structure and activity have been reported since the 
1960s, little is known about its regulation. Because CrAT is a freely reversible 
enzyme, its activity has long been thought to be regulated by substrate/product 
concentrations within the mitochondrial matrix. Chapter 3 suggests that while 
CrAT-mediated acetyl-CoA regulation facilitates the fasting to fed transition 
(Muoio et al. 2012), fatty acids counter-regulate the enzyme, allowing fat to be 
the primary fuel source. We suggest that lipids regulate CrAT within cultured cells 
and animal models both by sequestering carnitine into LCACs and by direct non-
competitive binding of long chain acyl-CoAs, thereby resulting in the 
accumulation of acetyl-CoA which causes PDH inhibition and mitochondrial 
stress. Results from these studies indicate that lipid-induced antagonism of 
acetyl-CoA efflux may contribute to low PDH activity and glucose disposal in the 
context of obesity and diabetes. 
Alternatively, we investigated the importance of acetyl-CoA buffering 
during exercise. Though multiple studies have focused on the forward CrAT 
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reaction (conversion of acetyl-CoA to acetylcarnitine), very little is known about 
the significance of the reverse reaction, despite the fact that CrAT is a freely 
reversible enzyme. Additionally, though CrAT is highly expressed in the skeletal 
muscle and heart, tissues specifically designed for energy output, little is known 
about the role of CrAT during exercise and other circumstances of energy 
demand. Therefore, we developed a skeletal muscle-specific CrAT knock out 
mouse model to analyze the role of CrAT in acetyl-CoA buffering during exercise. 
Chapter 4 suggests that CrAT-mediated maintenance of the acetyl-CoA pool may 
be critical to combat exercise-induced fatigue. 
In summary, we suggest the seminal importance of CrAT in fine-tuning the 
acetyl-CoA pool. These data demonstrate that CrAT deficiency leads to glucose 
intolerance and fatigue. Herein we discuss the important clinical implications of 
targeting the CrAT reaction and discuss potential future areas of study. 
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2 Methods 
2.1 Generation of CrATSM-/- Mice:  
As described by Muoio et al. 2012, CrATfl/fl mice were created using a conditional 
targeting vector was constructed using recombineering system. Isogenic DNA 
containing crat exons 3-13 was retrieved from genomic colony RP24-249K14 of 
C57BL/6J BAC genomic library via gap repair. The first loxP site was inserted 
into intron 8 and the loxP-neo-loxP into intron 11 via homologous recombination 
in E.Coli so that the exons 9-11 (1.0kb) were flanked by the first two loxP sites to 
generate crat targeting construct. Key elements were then confirmed by 
sequencing. This strategy deleted exons 9-11 and disrupted the coding 
sequence of exons 12-14 to obtain complete inactivation of CrAT enzyme 
function. For gene targeting, Not I-linearized crat targeting vector DNA consisting 
of 6.3kb 5’sequences (upstream of the first loxP site) and 1.8kb 3’ sequences 
was electroporated into C57BL/6J derived Bruce-4 embryonic stem (ES) cells. 
Correct homologous recombination in targeted clones was identified with Fidelity 
PCR at the 5’-end and 3’-end. The fragments produced from Fidelity PCR with 
these primers were sequenced to further confirm the correctness of 
recombination event and the location and sequence of loxP sites. Targeted ES 
were injected into albino B6 blastocysts (B6(Cg)-Tyrc-2J/J Jax Stock Number: 
000058). The heterozygotes (Cratfloxneo/+) were bred with ubiquitously 
expressed Cre (Ella-Cre) to generate heterozygous mice (Cratflox/+) without 
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PGK-neo. To generate muscle specific knockout mice for CrAT, Cratflox/+ were 
bred to myogenin-Cre recombinase mice, which were a generous gift from Eric 
Olson (UT Southwestern.) These mice were backcrossed for 10 generations to 
C57BL/6J mice before breeding to floxed CrAT. CrAT KO mice (Crat 
flox/flox;Myo-Cre) and control littermates (Crat flox/flox) were fed a standard 
chow diet (Purina Rodent Chow no. 5015, Purina Mills, St. Louis, MO, USA.)  
2.2 Mitochondrial Isolation:  
Skeletal muscle mitochondria were prepared based on the procedure of Kerner 
2001 with some modifications. Mouse gastrocnemius muscles were removed 
under anesthesia and placed in ice cold KMEM buffer (100mM KCl, 50 mM 
MOPS, 1 mM EGTA, 5 mM MgSO4, pH 7.4). Tissues were cleaned, blotted, 
weighed, finely minced, and suspended at a 10-fold dilution in KMEM plus 1mM 
ATP. The suspension was homogenized on ice using ten passes with a Potter-
Elvehjem homogenizer. KMEM/ATP buffer supplemented with 0.2% BSA was 
then added for a total 20 fold total dilution. The homogenate was centrifuged at 
500xg for 10 min at 4 °C. The supernatant was then centrifuged at 10,000xg for 
10 minutes at 4 °C and the pellet was resuspended in 500µL of KMEM/ATP/BSA 
buffer and centrifuged at 7000xg for 10 min at 4 °C to wash. The pellet was then 
resuspended in 500µL KMEM and centrifuged at 7000xg for 10 min at 4 °C, the 
resulting pellet being the mitochondrial fraction. The final pellet was resuspended 
in CelLytic lysis buffer (Sigma Chemicals, St. Louis, MO) and processed by 
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freeze fracturing three times and sonication at five times one second pulses on 
setting five using a Sonic Dismembrator from Fisher Scientific.  
2.3 Carnitine acetyltransferase activity:  
Carnitine-dependent conversion of acetyl-CoA to acetylcarnitine and free CoA 
was measured as previously described with minor modifications (1). Acetyl-CoA 
and 0.1 mM DTNB [5,5’dithiobis(2-nitrobenzoic acid)] were combined with 
purified enzyme, cell lysates or isolated mitochondria. The assay buffer included 
50 mM Tris and 1 mM EDTA in water at pH 7.8. CrAT activity was determined 
spectrophotometrically at 412 nm by evaluating the rate of reduction of DTNB by 
free CoA on a Spectramax M5 spectrophotometer (Molecular Devices). Samples 
were read for 2 minutes in the absence of carnitine to determine a baseline rate. 
Reactions were started with the addition of 5 mM L-carnitine (unless stated 
otherwise) and monitored every 20 seconds for 10 minutes at 25ºC. The 2 minute 
baseline rate was then subtracted from the final linear rate to yield a corrected 
rate.  Activity calculations were made using an instrument specific extinction 
coefficient for TNB of 16,029 M-1cm-1 determined using L-glutathione as a CoA 
donor and correcting for a path length of 0.641 cm (for a 0.2 ml reaction volume 
in NUNC 96-well plates).  All substrates were purchased from Sigma and re-
constituted in activity buffer. 
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2.4 Cell Culture:   
Primary human skeletal myocytes were grown and differentiated as previously 
described (Muoio et al.2002) in medium supplemented with 100µM L-carnitine 
(Sigma; ST. Louis, MO).  Human samples were obtained from the vastus lateralis 
muscle via needle biopsy at weights between 100 and 200 mg. Samples were 
rapidly placed in ice-cold Dulbecco’s modified Eagles media (DMEM; Life 
Technologies; Gaithersburg, MD), and trimmed of connective tissue and fat . 
Trypsin digestion was used to isolate satellite cells and plated for 1-3 hours in 3.0 
mL growth media (DMEM with human skeletal muscle SingleQuots from 
BioWhittaker (Walkersville, MD). Growth media was supplemented with 10% fetal 
bovine serum (FBS), 0.5 mg/ml BSA, 0.5 mg/ml fetuin, 20 ng/ml human 
epidermal growth factor, 0.39 g/ml dexamethasone, and 50 g/ml 
gentamicin/amphotericin B on uncoated T-25 tissue culture flasks to remove 
fibroblasts. Cells were then transferred to a type 1 collagen-coated T25 flask and 
cultured at 37ºC in a humidified incubator with 5% CO2. After the cells reached 
about 70% confluence, myoblasts were cultured on three collagen-coated p-100 
plates. When cells reached 70% confluence (generally 5-10 million cells), 0.5 
million cells per cryovile in were frozen down in 95% growth media, 5% DMSO 
overnight at -80, then in liquid nitrogen. For experimental purposes, each cryovile 
was thawed in a T-75 uncoated flask in growth media and split onto collagen-
coated plates. Once at 80% confluence, differentiation was induced by changing 
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to low-serum media containing 2% heat-inactivated horse-serum  Hyclone 
(Logan, UT), 0.5 mg/ml BSA (essentially fatty acid free; Sigma; St. Louis, Mo), 
0.5 mg/ml fetuin (Sigma; St. Louis, Mo), and 50 g/ml gentamicin/amphotericin B 
(Life Technologies Gaithersburg, MD). Media was changed every 2–3 days. 
Cytomegalovirus (CMV) promoter-driven recombinant adenoviruses encoding 
either β-galactosidase (rAdCMV-β-gal) or Myc-tagged rat carnitine 
palmitoyltransferase b (rAdCMV-CPT-1) were constructed, amplified and purified 
according to (Becker et al.1994).  On differentiation day 3, myotubes were 
exposed to 5.3x10-3 infectious units/cm2 rAdCMV-CPT-1. Metabolic analyses 
were performed 7d after virus treatment.  
2.5 DCFA Confocal Imaging:  
Primary human skeletal muscle or L6 skeletal muscle cells were used for 
confocal imaging. Upon 80% myoblast confluence, 100µM L-carnitine or water 
vehicle was added to differentiation media described in the cell culture section 
above. Media was changed every other day. On differentiation day 5, 250µM 
buthionine sulphoximine (BSO) was added as a 24 hour treatment to decrease 
total glutathione levels in the cell.  On differentiation day 6, cells were washed 
twice with PBS and then loaded with 5µM DCFA in differentiation media without 
phenol red for 30 minutes at 37ºC. A 5mM stock solution of DCFDA (Sigma; St. 
Louis, Mo) was made fresh each day in ethanol. Each treatment (+/- carnitine, +/- 
BSO), was present during the 30 minute DCFA treatment. Once DCFA was 
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added, cells were kept in the dark. After the 30 minute DCFA treatment, cells 
were washed twice with PBS and placed in phenol red free differentiation media 
+/- carnitine and +/- BSO to keep treatment conditions consistent. Cells were 
imaged in a Leica SP5 confocal microscope in a Ludin cube live cell chamber 
(humidified environment containing 5% CO2 at 37ºC). An argon 488 nm laser 
was used for DCFA detection. Laser exposure and smart gain fields were kept 
consistent between images.  
2.6 Western blots:  
Protein was isolated using CelLytic lysis buffer (Sigma Chemicals, St. Louis, 
MO). A bicinchoninic acid (BCA) kit (Sigma Chemicals, St. Louis, MO) was used 
to quantify protein. Protein (50µg from cell/tissue lysates) was separated by SDS-
PAGE, transferred to nitrocellulose, and incubated with antibodies prepared with 
5% milk in TBS-Tween. Secondary antibodies were HRP-conjugated and ECL 
detection reagent (Pierce, Rockford, IL) was used to visualize protein bands. The 
primary CrAT antibody was acquired as a generous gift generated in the 
laboratory of Dr. Fausto Hegardt. MemCode was used to determine protein 
loading and was obtained from Thermo scientific. 
2.7 RNA Analysis:  
RNA was isolated from mixed gastrocnemius using the total RNA isolation kit 
(Qiagen, Valencia, CA). RNA quality and quantity were determined using a 
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NanoDrop 8000 (Thermo Scientific). Using the IScript cDNA synthesis kit (Bio-
Rad, Hercules, CA), cDNA was made using 1µg RNA in a 20µL reaction volume. 
cDNA was then diluted 5 fold for RT-PCR. mRNA was assessed via RT-PCR 
using a Prism 7000 and TaqMan pre-designed/pre-validated FAM-labeled 
Assays-on-Demand (Applied Biosystems, Foster City, CA), and real-time master 
mix. Data was normalized to VIC-labeled 18S endogenous control gene 
expression (Applied Biosystems) using a duplexed RT-PCR reaction.  
2.8 Metabolite Analysis:   
Tissue and plasma samples were processed and analysed by the metabolomics 
and proteomics core facility at the Stedman Center core facility.  Acylcarnitine 
measurements were made using flow injection tandem mass spectrometry and 
sample preparation methods described in (An et al.2004 and Haqq et al.2005.) 
Data were acquired using the Micromass Quattro Micro TM systems and a model 
2777 autosampler, a model 1525 HPLC solvent delivery system and a data 
system controlled by MassLynx 4.0 operating systems (Waters, Millford, MA). 
Acyl-CoA measurements were analyzed using a method based on a the protocol 
used in Magnes et al. which employs the extraction protocol described in 
Deutsch et al.  CoAs were further purified by solid phase extraction described in 
Minkler et al.   Acyl CoAs were analyzed by flow injection using positive 
electrospray ionization and a Xevo TQS, triple quadrupole mass spectrometer 
(Waters, Milford, MA) using methanol/water (80/20, v/v) containing 30 mM 
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ammonium hydroxide as the mobile phase. Spectra were acquired in the 
multichannel acquisition mode monitoring the neutral loss of 507 amu 
(phosphoadenosine diphosphate) and scanning from m/z 750- 1060.  
Heptadecanoyl CoA was used as an internal standard. Endogenous CoAs were 
quantified using calibrators prepared by spiking skeletal muscle homogenates 
with known CoAs  (Sigma, St. Louis , MO) having saturated acyl chain lengths 
between C0- C18..  Corrections for the heavy isotopes to the adjacent m+2 
spectral peaks for each chain length cluster were made empirically by referring to 
the observed spectra for the analytical standards. 
2.9 Phosphocreatine and Creatine Content:  
Phosphocreatine (PCr) and creatine analysis was measured according to 
Bergmeyer 1974 and Harris et al.1974. Before analysis was conducted, a 
skeletal muscle perchloric acid (PCA) extraction was completed. 0.5M PCA (10M 
EDTA) was added at 60x sample volume to ground freeze-dried samples and 
vortexed. These samples were then stored on ice for 5 min with intermittent 
vortexing throughout. Samples were then centrifuged at 7000 rpm for 5 min 
(4˚C). 80% of the PCA volume added was then removed and ¼ of this volume 
was added back with 2.2M KHCO3. Samples were then vortexed 2-3 times on ice 
until the bubbling stopped. The samples were then centrifuged at 7000 rpm for 
15 min (4˚C).  
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PCr analysis was run at 340nm in cuvettes with 25µL muscle extract 
added to 225µL reagent. The reagent consisted of 100mM triethanolamine (pH 
7.5,) 10mM mg(Ac)24H2O, 1mM EDTA.Na2.2H2O, 1mM DTT, 1mM 
NADP.Na2.4H2O (this must be made fresh,) 0.04mM ADP.Na2.2H2O, 5mM 
glucose, 0.67µL per sample G6PDH (Roche, Basel Switzerland) and 178.75µL 
per sample water. Cuvettes were then read for background absorbance. 2µL 
hexokinase (Roche, Basel Switzerland) and 2µL CPK at 15mg/ml (Sigma; St. 
Louis, Mo) were then added. PCr was measured after a 4-5 minute reaction.  
Creatine analysis was run at 340nm in cuvettes. 20µL muscle extract was 
added to 250µL reagent. The reagent consisted of 100mM glycine, 5mM 
mg(Ac)2.4H2O pH 9, 30mM KCl, 1.5mM ATP.Na2.3.5H2O, 1mM PEP, 0.15mM 
NADH (this must be made fresh,) 0.45µL per reaction LDH (Roche, Basel 
Switzerland), 0.45µL per reaction pyruvate kinase (Roche, Basel Switzerland) 
and 134.5µL per reaction H2O.  Cuvettes were read for background absorbance. 
10µL creatine phosphokinase (Sigma; St. Louis, Mo, made up at 15mg/mL in 
H2O) was added and creatine was assessed at 340nm.  
2.10 Glycogen Content:  
Glycogen was assessed using approximately 20 mg of powdered skeletal 
muscle. The powdered tissue was added to 0.5 ml of 1 N HCl secured in 2.0-ml 
screw top tubes and homogenized at 25K RPM for 30 seconds using a sawtooth, 
rotor/sator homogenizer VDI-12 with 5 mm probe (VWR; Radnor, Pennsylvania). 
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The samples were then boiled for 90 minutes. The tubes were cooled to room 
temperature and 0.5 ml of 1N NaOH was added. Samples were then spun at 
14,000xg for 10 minutes at room temperature. Glycogen content was assessed 
in the sample supernatant. 20µL in triplicate was assessed at 340nm after 
addition of glucose assay reagent (Sigma; St. Louis, Mo). The glucose standard 
curve was made up using powdered glucose (Sigma; St. Louis, Mo), in 1:1 acid: 
base (pH neutral) serially diluted from 5 mM to 0.195 mM glucose. Glycosyl units 
were calculated based on the 1 mL starting supernatant and expressed as µmole 
glycosyl unit per gram starting wet weight of tissue.  
2.11 Lactate Content:  
Lactate was assessed at 340nm. Lactate assay buffer consisted of 175mM 
hydrazide sulfate, 68mM glycine, 2.9mM EDTA, and 11.3mM NAD+ (which must 
be added fresh each day,) pH 9.5. Lactate standard (Sigma; St. Louis, Mo) was 
made up at 3, 1.5, 0.75, 0.375 and 0.1875mM. 20µL sample or standard was 
added with 200µL assay buffer. Background absorbance was measured. 10µL 
LDH enzyme (Sigma; St. Louis, Mo,) made up at 500 units/ml in water, was then 
added rapidly and absorbance was monitored for 60 minutes. Upon kinetic 
plateau, final absorbance was taken. Lactate was determined according to the 
standard curve.  
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2.12 Nucleotide Profiling:  
Nucleotides were measured by a method modified from a previously reported 
LC-MS/MS method (Cordell et al, 2008). An EDL (10-13 mg) was transferred to a 
2 mL tube prechilled in liquid nitrogen.  A solution of methanol (200 µL) 
containing internal standards was added as well as a prechilled 5 mm glass bead 
(Glen Mills Inc., Clifton, NJ, USA).  Tissues were lysed in a Qiagen Tissue Lyser 
II for 2 x 30s at a frequency of 30/s. Chilled water was added to bring the mixture 
to 300 µL and the samples were allowed to extract for 15 min at -20 oC. Hexane 
(300 µL) was added to each tube, and the tubes were thoroughly mixed. The 
tubes were then centrifuged and the bottom layer collected in a fresh tube and 
centrifuged again. The supernatant was transferred to a 96-well plate for analysis 
by liquid chromatography tandem mass spectrometry. Chromatographic 
separations were performed using an Agilent Technologies (Santa Clara, CA) 
1200 HPLC system and a Chromolith FastGradient RP-18e 50-2mm column 
(EMD Millipore, Billerica, MA, USA) under the following conditions. Injection 
volume was 2 µL. Mobile phase A was 95% water 5% methanol and 5 mM 
dimethylhexylamine. Mobile phase B was 20% water 80% methanol and 10 mM 
dimethylhexylamine. Flow rate was set to 0.3 mL/min and column temperature 
was 40 oC. A 22 min gradient method (t=0, %B=0; t=1.2, %B=0; t=22, %B=40) 
was run followed by a 3 min wash and 7 min equilibration. Flow was directed to 
an Agilent 6410 Triple Quadrupole MS (Santa Clara, CA) and source conditions 
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were set to 4000 V capillary voltage, 350 oC gas temperature, 12 L/min gas flow, 
and 30 psi nebulizer flow.   All nucleotides were detected in negative ion MRM 
mode based on a characteristic fragmentation reaction (table 1). Quantitation of 
metabolites is based on the inclusion of isotope labeled internal standards and 
an external calibration using nucleotide standards in a mixed muscle matrix.  
Table 1: Characteristic Fragmentation Reaction for Nucleotide Detection 
Compound Prec. (m/z) MS1 Res 
Prod. 
(m/z) MS2 Res Frag (V) CE (V) RT 
Delta 
RT 
Acadesine 257 wide 125 wide 110 15 1.2 3 
Adenine 134 wide 107 wide 120 15 1.6 3 
Guanosine 282 wide 150 wide 140 12 1.7 3 
SAH 383 wide 134 wide 90 30 2.5 3 
Adenosine 266 wide 134 wide 80 27 3 3 
NAD 662.1 wide 540.1 wide 105 13 4.2 3 
CMP 322 wide 211 wide 140 9 5.1 3 
UMP 323 wide 111 wide 120 24 5.9 3 
εNAD 686.1 wide 564.1 wide 115 15 6.7 3 
UDP-galactose 565 wide 323 wide 160 24 6.7 3 
GMP 362 wide 79 wide 95 25 6.9 3 
IMP 347 wide 79 wide 120 39 7.1 3 
GDP-mannose 604 wide 424 wide 160 30 7.4 3 
AMP IS 361 wide 144 wide 80 37 9 3 
13C10-AMP 356 wide 139 wide 80 37 9 3 
AMP 346 wide 134 wide 80 37 9 3 
ADP-ribose 558 wide 346 wide 160 30 9.5 3 
MTA 296 wide 134 wide 80 12 9.5 3 
XMP 363 wide 151 wide 95 30 11.4 3 
CDP 402 wide 159 wide 130 27 11.5 3 
NADH 664.1 wide 397.1 wide 130 33 11.6 3 
UDP 403 wide 159 wide 110 27 12 3 
GDP 442 wide 150 wide 140 25 12.4 3 
NADP 742 wide 620.1 wide 120 15 12.7 3 
13C10,15N5-ADP 441 wide 159 wide 130 27 14 3 
13C10-ADP 436 wide 159 wide 130 27 14 3 
ADP 426 wide 159 wide 130 27 14 3 
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13C9-CTP 491 wide 159 wide 160 33 15.9 3 
CTP 482 wide 159 wide 160 33 15.9 3 
dCTP 466 wide 159 wide 120 36 16 3 
13C9-UTP 492 wide 159 wide 120 36 16.4 3 
UTP 483 wide 159 wide 120 36 16.4 3 
13C10-GTP 532 wide 434 wide 130 22 16.5 3 
GTP 521.9 wide 424.1 wide 130 22 16.5 3 
S-AMP 462 wide 134 wide 150 39 16.7 3 
dGTP 506 wide 355 wide 130 18 17 3 
dTTP 481 wide 159 wide 110 33 17.2 3 
13C10,15N5-ATP 521 wide 159 wide 115 33 17.5 3 
13C10-ATP 516 wide 159 wide 115 33 17.5 3 
ATP 506 wide 159 wide 115 33 17.5 3 
dATP 490 wide 392 wide 110 21 18.1 3 
NADPH 371.6 wide 304.1 wide 105 10 18.4 3 
 
2.13 Permeabilized Muscle Fiber Bundles (PmFB):  
PmFB were prepared based on described methods (Anderson et al.2007, Perry 
et al.2011), which were adapted from previous studies (Tonkongi et al.2003, 
Kuznetsov et al.1996). Extracted muscle was placed in ice-cold biops buffer 
containing (in mM) 50MES, 7.23K2EGTA, 2.77 CaK2EGTA, 20 imidazole, 
0.5DTT, 20 taurine, 5.7 ATP, and 6.56 MgCl2-6 H2O (pH 7.1, 290mOsm). The 
muscle was trimmed of connective tissue and fat and dissected into small 
portions. Small muscle bundles (2-7mm, 0.9-2.0 mg wet weight) were prepared 
from each mouse. Each bundle was gently separated along its longitudinal axis 
on ice with a pair of needle-tipped forceps under magnification (MX6 
stereoscope, Leica Microsystems, Inc., Wetzlar, DE). Bundles were then 
incubated on a rotor with 40µg/mL saponin in biops buffer for 30 minutes at 4ºC. 
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Saponin is a cholesterol-specific detergent that selectively permeabilizes the 
sarcolemmal membranes while keeping the mitochondrial membranes (which 
contain low levels of cholesterol), largely intact (Veksler et al.1987, Kuznetsov et 
al.2007). Fiber bundles were then washed for 10 minutes on a rotor at 4ºC in 
respiration buffer containing (in mM) 105 K-MES, 30KCl, 1 EGTA, 10KH2PO4 and 
5 MgCl2-6 H2O with 5mg/ml BSA (pH 7.4, 290 mOsm).  
 Mitochondrial oxygen consumption was measured in the 
OROBOROS Oxygraph-2k (OROBOROS Instruments, Corp., Innsbruck, AT). 
Fiber bundles were placed on blotting paper for 10 seconds and immediately 
weighed and transferred into the OROBOROS chamber containing 2mL 
respiration buffer and constant stirring at 750rpm. Experiments were run at 37ºC, 
beginning with ~350µM O2. Chambers were re-oxygenated if oxygen content fell 
below 300µM.  
2.14 Exercise Studies:  
Because of the inherent subjectivity of treadmill running to exhaustion, exercise 
studies were carried out in a blind fashion. Before exercise testing, mice were 
acclimated to the treadmill for three days prior to the study. Acclimation consisted 
of a three minute run with one minute at each of the first three speeds in the 
respective protocol being tested.  
Endurance exercise was analyzed at a fixed slope of 10º. Mice began 
running at 8m/min. Treadmill speed was increased 2m/min every 15 minutes until 
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16m/min was attained. At this point, the treadmill was held at a consistent speed 
until exhaustion. Exhaustion was defined as remaining on the shocker plate for 
more than 10 seconds with nudging. 
The transition from endurance to high intensity exercise protocol was run 
with a fixed slope of 10º. Similar to the endurance protocol described above, 
mice began running at 8 m/min and increased 2m/min every 15 minutes for 1 
hour total. After the initial hour, the mice were transitioned into a higher intensity 
exercise with 1 minute at 20m/min, then 10 minutes at 23 m/min, with an 
increase of 3.5m/min every 10 min until exhaustion.  
Exercise capacity during high intensity running was determined using an 
enclosed treadmill (Columbus instruments,) attached to the Comprehensive 
Laboratory Animal Monitoring System (CLAMS) with a fixed incline of 10º. 3-mo-
old mice were run at 14 m/min with increasing speed by 3 m/min every 3 minutes 
until exhaustion. Measurements were collected every 30 seconds during which 
air flow was set to 0.6 l/min. 
2.15 Isolated muscle Stimulation and Acetylcarnitine Oxidation 
Studies:  
Braided silk suture loops were attached to muscle tendons and excised from the 
mouse. Muscles were placed in pre-warmed KHB buffer (pH 7.4) which 
contained (in mmol/l) 118 NaCl, 4.7 KCl, 2.52 CaCl2, 1.64 MgSO4, 24.88 NaCO3, 
1.18 KH2PO4, 5.55 glucose and 2.0 Na-pyruvate. After placement in the system, 
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muscles were tensed to 1 gram and allowed to relax for 15 minutes. Muscles 
were then re-tensed to 1 gram and allowed to rest 5 minutes. This tense/5 minute 
rest was repeated three times before initiation of stimulation. KHB buffer was 
used in muscle transport and tensing, while low glucose KHB (+2mM glucose, no 
pyruvate) was used during stimulation. The following stimulation protocol was 
used unless otherwise stated: stimulation rate: 60pps, delay: 2000ms, duration: 
300ms, volts: 20 per chamber. O2 flow and temperature (25ºC) were kept 
constant throughout stretching and stimulation. Acetylcarnitine (Sigma; St. Louis, 
Mo), was made up at 1 M in H2O and added at a final concentration of 5 mM to 
stimulating muscles 30 seconds after initiation of contraction. This allowed for 
normalization of contracting muscles prior to acetylcarnitine addition. 
Acetylcarnitine oxidation was assessed by capturing 14CO2 from 200µM [1-
14C]acetylcarnitine (ARC 1615) during rest or stimulation in a radnoti 2mL tissue 
bath system. Oxidation studies were done in low glucose KHB buffer with 3 
mg/mL HEPES added.  
2.16 Statistics:  
JMP software version 7.0 (SAS Institute, Cary, NC) was used to perform 
multivariate correlation analyses of metabolites measured in Zucker diabetic fatty 
(ZDF) rats and lean controls. Other statistical analyses were performed using 
SigmaStat (SysStat Software, Inc., Point Richmond, CA) or the Microsoft Excel 
statistical package. Within-group responses to experimental manipulations were 
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evaluated using a paired t test, where appropriate. All data are presented as 
mean ± S.E., and the level of significance was established a priori at p less than 
or equal to 0.05. 
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3 Obesity and Lipid Exposure Inhibit Carnitine 
Acetyltransferase Activity 
Objective: Carnitine acetyltransferase (CrAT) is a mitochondrial matrix enzyme 
that catalyzes the interconversion of acetyl-CoA and acetylcarnitine. Recent 
studies have shown that enhanced or diminished forward flux through the CrAT 
reaction results in corresponding changes in total body glucose tolerance and 
muscle activity of PDH, a mitochondrial enzyme complex that regulates glucose 
oxidation.  Because PDH activity is feedback inhibited by acetyl-CoA and 
negatively regulated by obesity and high fat feeding, we questioned whether 
overnutrition and/or lipid exposure might likewise diminish CrAT activity.   
Methods: Tandem mass spectrometry-based metabolic profiling was used to 
investigate the relationship between muscle content of lipid intermediates and 
CrAT activity in multiple rodent models of obesity.  Additionally, the direct effect 
of lipid exposure on CrAT activity was examined using purified enzyme, isolated 
mitochondria and human skeletal myocytes (HSkMC) grown in culture.  
Results:  CrAT specific activity was decreased in muscles from obese and 
diabetic rodents, despite increased protein abundance.  This reduction in enzyme 
activity was accompanied by muscle accumulation of long chain acylcarnitines 
and acyl-CoAs, and a decline in the acetylcarnitine/acetyl-CoA ratio. In vitro 
assays of CrAT activity demonstrated that palmitoyl-CoA acts as a direct mixed-
model inhibitor of CrAT, with an IC50 ranging from 12 µM to 178 µM.  Similarly, 
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in primary HSkMC grown in culture, nutritional and genetic manipulations that 
promoted mitochondrial influx of fatty acids resulted in accumulation of long chain 
acylcarnitines but a pronounced lowering of free carnitine and CrAT-derived short 
chain acylcarnitines.   
Conclusions: These results show that nutrient overload inhibits CrAT activity 
and suggest that lipid-induced antagonism of this enzyme might contribute to 
decreased PDH activity and glucose disposal in the context of obesity and 
diabetes. 
3.1 Introduction: 
L-Carnitine is a conditionally essential nutrient that serves as a substrate for a 
family of acyltransferase enzymes that catalyze the interconversion of acyl-CoAs 
and acylcarnitines. Unlike their acyl-CoA precursors, acylcarnitines can be 
transported across cellular membranes. Accordingly, carnitine is best known for 
its obligatory role in shuttling long chain acyl-CoAs from the cytoplasm into the 
mitochondria matrix for fatty acid oxidation, a function that is mediated by the 
outer mitochondrial membrane enzyme, carnitine palmitoyltransferase 1 (CPT1).  
The long chain acylcarnitine products of CPT1 are transported across the inner 
mitochondrial membrane by carnitine acylcarnitine translocase and then 
converted back to long chain acyl-CoAs by carnitine palimitoyltransferase 2 
(CPT2), also localized to the inner membrane.  By contrast, carnitine 
acetyltransferase (CrAT) resides in the mitochondrial matrix and has strong 
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preference for short chain acyl-CoA intermediates of fatty acid, glucose and 
amino acid catabolism.  Thus, CrAT facilitates trafficking and efflux of carbon 
intermediates from the mitochondrial compartment to other cellular and 
extracellular sites.   
 
Recent animal studies have established important roles for L-carnitine and 
CrAT in regulating glucose homeostasis and mitochondrial substrate switching 
(Muoio et al. 2012).  By converting acetyl-CoA to acetylcarnitine, CrAT not only 
buffers the mitochondrial acetyl-CoA pool but also regenerates free CoA, both of 
which influence the activities of several oxidative enzymes. Dietary L-carnitine 
supplementation administered to obese or diabetic rodents promotes 
acetylcarnitine efflux and encourages carbon flux through pyruvate 
dehydrogenase (PDH; Noland et al. 2009), the enzyme complex that connects 
glycolysis to glucose oxidation and which is feedback inhibited by its product, 
acetyl-CoA. Fitting with the notion that CrAT mitigates acetyl-CoA inhibition of 
PDH, mice with muscle-specific deletion of crat show impaired switching from 
fatty acid to glucose-derived fuels during the fed-to-fasted transition (Muoio et al. 
2012). These perturbations in fuel metabolism were associated with 
intramuscular accumulation of short, medium and long chain acyl-CoAs, 
decreased PDH activity and development of whole body insulin resistance 
(Muoio et al. 2012).   
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Because PDH activity, substrate switching and glucose tolerance are 
negatively impacted by obesity and high fat feeding, the present study sought to 
determine whether these nutritional and pathophysiological conditions might 
likewise impinge upon CrAT activity.  To this end, we examined changes in 
acylcarnitine/acyl-CoA balance, CrAT expression and CrAT activity in a variety of 
rodent and cell culture models of nutrient-induced metabolic dysfunction.  We 
found that CrAT activity was indeed decreased in response to genetic diabetes, 
high fat feeding and lipid exposure.  Taken together with previous studies, these 
results suggest that diminished CrAT activity might contribute to low PDH activity 
and impaired glucose disposal in the context of obesity and diabetes. 
 
3.2 Materials and Methods   
Animals.  Animal studies were approved by the Duke University Institutional 
Animal Care and Use Committee. Male Wistar rats (150-175 g, Charles River) 
were single housed and allowed ad libitum access to food and water. Animals 
were randomly selected to receive twenty weeks of either a low fat diet 
(D12450B) or a 45% high fat diet (D12451; Research Diets) beginning at 3 
months of age. Male Zucker diabetic fatty (ZDF) rats and lean controls (Charles 
River) were allowed ad libitum access to standard chow and water before harvest 
at 3 months of age.  Rats were sacrificed after intraperitoneal injection of 
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Nembutal with the dose of 25 mg/kg body weight. Gastrocnemius samples were 
clamp frozen and stored at -80oC. Tissues were ground into powder and 
processed in CelLytic buffer (Sigma Chemicals, St. Louis, MO) by freeze 
fracturing three times and sonication at five times one second pulses on setting 
five. 
 
Mitochondrial Isolation.  Skeletal muscle mitochondria were prepared according 
to (Kerner et al. 2001) with modification. Mouse gastrocnemius muscles were 
removed under anesthesia and placed in ice cold KMEM buffer (100mM KCl, 50 
mM MOPS, 1 mM EGTA, 5 mM MgSO4, pH 7.4). The tissue was cleaned, 
blotted, weighed, finely minced, and suspended at a 10-fold dilution in KMEM 
plus 1mM ATP. The suspension was homogenized on ice using ten passes with 
a Potter-Elvehjem homogenizer. KMEM/ATP buffer supplemented with 0.2% 
BSA was then added to achieve a 20- fold dilution. The homogenate was 
centrifuged at 500xg for 10 min at 4 °C. The supernatant was then centrifuged at 
10,000xg for 10 minutes at 4 °C and the pellet was resuspended in 500µL of 
KMEM/ATP buffer and centrifuged at 7000xg for 10 min at 4 °C to wash. The 
pellet was resuspended in 500uL KMEM and centrifuged at 7000xg for 10 min at 
4 °C.  The resulting mitochondrial pellet was resuspended in CelLytic lysis buffer 
(Sigma Chemicals, St. Louis, MO) and processed by freeze fracturing three times 
and sonication at five times one second pulses on setting five.  
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Carnitine acetyltransferase activity. Carnitine-dependent conversion of acetyl-
CoA to acetylcarnitine and free CoA was measured as previously described with 
minor modifications (Muoio et al.2012). Acetyl-CoA and 0.1 mM DTNB 
[5,5’dithiobis(2-nitrobenzoic acid)] were combined with purified enzyme, cell 
lysates or isolated mitochondria. The assay buffer included 50 mM Tris and 1 
mM EDTA in water at pH 7.8. CrAT activity was determined 
spectrophotometrically at 412 nm by evaluating the rate of reduction of DTNB by 
free CoA on a Spectramax M5 spectrophotometer (Molecular Devices). Samples 
were read for 2 minutes in the absence of carnitine to determine a baseline rate. 
Reactions were started with the addition of 5 mM L-carnitine (unless stated 
otherwise) and monitored every 20 seconds for 10 minutes. The 2 minute 
baseline rate was then subtracted from the final linear rate to yield a corrected 
rate.  Activity calculations were made using an instrument specific extinction 
coefficient for TNB of 16,029 M-1cm-1 determined using L-glutathione as a CoA 
donor and correcting for a path length of 0.641 cm (for a 0.2 ml reaction volume 
in NUNC 96-well plates).  All substrates were purchased from Sigma and re-
constituted in activity buffer. 
 
Western blots. Protein was isolated using CelLytic lysis buffer (Sigma Chemicals, 
St. Louis, MO). A bicinchoninic acid (BCA) kit (Sigma Chemicals, St. Louis, MO) 
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was used to quantify protein. Protein (50µg from cell/tissue lysates) was 
separated by SDS-PAGE, transferred to nitrocellulose, and incubated with 
antibodies prepared with 5% milk in TBS-Tween. Secondary antibodies were 
HRP-conjugated and ECL detection reagent (Pierce, Rockford, IL) was used to 
visualize protein bands. Protein expression was normalized to total protein as 
determined by MemCode staining (Thermo Scientific). The primary CrAT 
antibody was a generous gift from the laboratory of Dr. Fausto Hegardt. 
 
Metabolic profiling.  Tissue and plasma samples were processed and analysed 
by the Sarah W. Stedman Nutrition and Metabolism metabolomics/biomarker 
core laboratory.  Acylcarnitine measurements were made using flow injection 
tandem mass spectrometry and sample preparation methods described in (An et 
al. 2004, Haqq et al. 2005). Acyl-CoA esters were analyzed using a method 
based on a previously published report (Magnes et al. 2005) which relies on the 
extraction procedure described by (Deutsch et al. 1994).  The CoAs were further 
purified by solid phase extraction as described by (Minkler et al. 2008). 
 
Cell Culture.  Primary human skeletal muscle myocytes (HSkMC) were grown 
and differentiated as previously described (Muoio et al. 2002), but with the 
addition of 100µM L-carnitine in the differentiation medium.  Cytomegalovirus 
(CMV) promoter-driven recombinant adenoviruses (rAd) encoding either β-
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galactosidase (rAd-β-gal) or Myc-tagged rat carnitine palmitoyltransferase b (rAd-
CPT-1) were constructed, amplified and purified as previously described (Becker 
et al. 1994).  On differentiation day 3, myotubes were treated overnight with 
5.3e10-3 infectious units/cm2 rAd-β-gal or rAd-CPT-1. Medium was replaced on 
differentiation day 4.  On day 6, cells were treated with differentiation medium 
containing 1% BSA, alone or complexed with 100 µM or 500 µM 1:1 
oleate:palmitate, along with 1 mM L-carnitine. Conditioned culture medium and 
cell lysates were harvested on differentiation day 7.  Cells were washed twice 
with PBS, flash frozen in liquid nitrogen and lysates were harvested in water after 
scraping.  Specimens were submitted to the Stedman Metabolomics Core 
Laboratory for profiling of acylcarnitines.  Metabolite concentrations were 
normalized to total cellular protein. Similarly, rAD-CrAT treatment and processing 
was done according to (Noland et al. 2009). 
 
Statistics. Statistical analyses were performed using SigmaStat (SysStat 
Software, Inc., Point Richmond, CA) or the Microsoft Excel statistical package. 
Within-group responses to experimental manipulations were evaluated using a 
paired t test, where appropriate. IC50 values were calculated using Prism 
Graphpad software. Data are presented as means±S.E., and the level of 
significance was established a priori at p less than or equal to 0.05. 
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3.3 Results 
Obesity and Diabetes Disrupt Acyl-CoA Buffering:  Obesity and diabetes 
are associated with muscle accumulation of medium and long chain 
acylcarnitines (LCAC) (Noland et al. 2009, Koves et al. 2008).  Because these 
intermediates are presumed to be in equilibrium with their cognate acyl-CoA 
precursors (Brass et al. 1980, Carter et al. 1981), here we sought to examine 
tissue fluctuations in these two interconnected metabolite pools. As expected, 
LCAC and long chain acyl-CoAs were increased (up to 4.6 fold) in both heart and 
gastrocnemius muscles from Zucker diabetic fatty (ZDF) rats compared to lean 
controls, and to a lesser degree from those fed a high fat (HF) diet versus a low 
fat (LF) control diet (Table 2 and Figure 6).  Despite pronounced accumulation of 
LCAC and MCAC species in heart and muscle of diabetic and/or obese rodents, 
acetylcarnitine (C2) levels were unchanged and tended to decrease in these 
same tissues (Table 2).  Muscle levels of acetyl-CoA, the principal substrate of 
CrAT, were unchanged in the diabetic model but increased 1.8-fold in 
gastrocnemius muscles from rats fed a high fat versus low fat diet. 
  
  
  
  
  
  
  
  
    
52  
Table 2: Obesity and Diabetes Disrupt Acyl-CoA Buffering. 
Tandem mass spectrometry was used to assess total long chain acylcarnitines (LCAC), long 
chain acyl-CoAs (LCACoA), medium chain acylcarnitines (MCAC), medium chain acyl-CoAs 
(MCACoA), acetylcarnitine and acetyl-CoA.  Metabolites were measured in tissue homogenates 
from obese Zucker diabetic fatty (ZDF) rats and lean control animals, and from adult Wistar rats 
fed a 10% low fat (LFD) or 45% high fat diet (HFD) for twenty weeks.  Data are expressed as 
pmol/mg tissue and represent means ± S.E. from 5-8 animals per group. * p<0.05, lean vs. 
obese.  
  
	  	                    Heart  Gastrocnemius Muscle  Gastrocnemius Muscle 
	  	      Lean    ZDF    Lean    ZDF    LFD    HFD 
Total LCAC 
(pmol/mg tissue) 
  7.7±2.4 35.6±7.1*   8.3±1.5 28.6±3.5*   2.3±0.5 3.4±0.6 
Total LCACoA 
(pmol/mg tissue) 
  12.6±3.6 41.4±5.8*   5.0±0.3 11.2±0.9*   7.2±0.4 11.2±1.0* 
Total MCAC 
(pmol/mg tissue)  
  0.6±0.2 2.0±0.4*   1.1±0.2 3.5±0.4*   0.6±0.2 0.7±0.1 
Total MCACoA 
(pmol/mg tissue)  
  5.3±0.6 6.3±0.5   1.6±0.2 1.9±0.1   2.0±0.2 2.1±0.2 
Acetylcarnitine 
(pmol/mg tissue)  
  181.6±16.3 135.6±16.3   153.0±10.7 153.6±8.8   76.6±12.2 54.4±7.4 
Acetyl-CoA 
(pmol/mg tissue)  
  15.4±1.4 16.0±0.5   1.8±0.2 2.2±0.07   0.58±0.02 1.0±0.07* 
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Figure 6: Long Chain Acylcarnitine and Acyl-CoA Profiling of Muscle from 
Obese and Diabetic Rats.  
Tandem mass spectrometry was used to assess long chain acylcarnitines (A-C) and long chain 
acyl-CoAs (D-E) in tissue homogenates prepared from lean (filled bars) and obese (open bars) 
rats. Acylcarnitines measured in (A) heart and (B) gastrocnemius muscles from obese Zucker 
diabetic fatty (ZDF) rats and lean controls; and (C) gastrocnemius muscles from Wistar rats fed a 
10% low fat or 45% high fat diet for twenty weeks. Acyl-CoAs measured in (D) heart and (E) 
gastrocnemius muscles from obese Zucker diabetic fatty (ZDF) rats and lean controls; and (F) 
gastrocnemius muscles from Wistar rats fed a 10% low fat or 45% high fat diet for eight weeks.   
Data represent means ± S.E. from 5-8 animals per group.  * p<0.05 lean vs. obese. 
  
      
CrAT specific activity is diminished in rodent models of obesity and 
diabetes. Collectively, the results in Table 2 revealed discordant fluctuations in 
the myocellular acyl-CoA and acylcarnitine pools in response to obesity and 
diabetes.  Figure 7A highlights the obesity-associated shift in the 
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acetylcarnitine/acetyl-CoA ratio, which decreased 23 and 58% in muscles from 
the ZDF and HF fed rats, respectively, as compared to controls. Because a 
similar imbalance resulted from muscle-specific deletion of crat (Muoio et al. 
2012), we questioned whether these observations might be indicative of reduced 
enzyme activity.  To test this possibility we first measured changes in CrAT 
mRNA and protein expression in the same models.  Interestingly, CrAT mRNA 
levels tended to increase (Figure 7B) whereas CrAT protein abundance (Figure 
7C and D) was doubled in gastrocnemius muscles from ZDF compared to lean 
control rats.   Likewise, the obesogenic HF diet did not affect CrAT mRNA but 
increased protein abundance by 24% compared to the LF diet controls (Figure 
7B-D).   Despite the 2-fold rise in CrAT protein levels measured in tissue lysates 
from ZDF compared to control rats, CrAT activity (measured in homogenates 
prepared from the same tissues) was elevated by only 20% (Figure 7E).  
Similarly, CrAT activity was unchanged in homogenates prepared using muscles 
from the HF-fed rats, despite a 24% increase in CrAT protein levels (Figure 7E). 
Thus, when CrAT activity was corrected for protein abundance, specific activity of 
the enzyme was reduced 30% and 26%, in the ZDF and HF diet models, 
respectively (Figure 7F). Similar results were observed in heart homogenates 
from ZDF compared to lean control rats (Figure 8) and skeletal muscle 
homogenates of C57BL6/J mice fed a HF compared to a LF diet (Figure 9).  
Thus, this response is consistent across tissues and species. 
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Figure 7: CrAT Specific Activity is Diminished by Obesity and Diabetes.  
Gastrocnemius muscles were harvested from obese Zucker diabetic fatty (ZDF) rats and lean 
control animals, and from adult Wistar rats fed a 10% low fat or 45% high fat diet for twenty 
weeks. (A) Tandem mass spectrometry-based measurement of the acetylcarnitine:acetyl-CoA 
ratio.  (B) CrAT mRNA expression normalized to 18S. (C) Representative western blots and (D) 
protein abundance of CrAT normalized to the MEMCode stain. (E) Total CrAT enzyme activity 
and (F) CrAT specific activity corrected for CrAT protein abundance. Data are expressed as fold 
change relative to the lean control group and represent means ± S.E. of 5-8 animals per group.    
* p<0.05 lean vs. obese. 
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Figure 8: CrAT Specific Activity is Diminished in the Diabetic Heart. 
Hearts were harvested from obese Zucker diabetic fatty (ZDF) rats and lean control animals. (A) 
Tandem mass spectrometry-based measurement of the acetylcarnitine:acetyl-CoA ratio.  (B) 
CrAT mRNA expression normalized to 18S. (C) Representative western blots and (D) protein 
abundance of CrAT normalized to the MEMCode stain. (E) Total CrAT enzyme activity and (F) 
CrAT specific activity corrected for CrAT protein abundance. Data are expressed as fold change 
relative to the lean control group and represent means ± S.E. of 5-8 animals per group. * p<0.05 
lean vs. ZDF. 
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Figure 9: High Fat Feeding Decreases CrAT Specific Activity in Mouse 
Muscle. 
Gastrocnemius muscles were harvested from mice fed a 10% low fat (LFD) or 45% high fat diet 
(HFD) for 4 weeks and used for (A) tandem mass spectrometry-based measurement of 
acetylcarnitine content, and (B) assessment of CrAT specific activity corrected for CrAT protein 
abundance. Data are expressed as fold change relative to the lean control group and represent 
means ± S.E. of 5-8 animals per group. * p<0.05 10% vs. 45% HFD.  
 
Long chain acyl-CoAs inhibit CrAT activity.    Results in Figure 7 revealed 
a negative relationship between intramuscular lipid accumulation and CrAT 
activity.  Relevant to this observation, earlier studies reported that long chain 
acyl-CoAs inhibited the activity of purified pigeon CrAT (Chase et al. 1967, 
Huckle et al. 1983, Mittal et al. 1980).  Here, we sought to examine the inhibitory 
actions of palmitoyl-CoA on the activity of rat and mouse CrAT when assayed in 
a more native environment.  To this end, we first compared CrAT substrate 
preference and enzyme kinetics using purified pigeon protein (Figure 10A), 
lysates of HSkMC treated with a rAd encoding rCrAT (Figure 10B), and isolated 
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mitochondria from mouse grastrocnemius muscle (Figure 10C).  Consistent with 
earlier reports, both pigeon and rodent CrAT strongly preferred short chain acyl-
CoAs and had essentially no activity with palmityol-CoA.  Preference for specific 
short chain substrates differed by species. Whereas purified pigeon CrAT 
preferred propionyl-CoA>acetyl-CoA>butyryl-CoA, mouse and rat CrAT had 
greatest preference for butyryl-CoA, followed by propionyl-CoA>acetyl-CoA 
(Figure 10B and C).  Affinity for L-carnitine was similar in the three systems 
assayed, each showing a Km of approximately 0.10 mM (Figure 10D) 
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Figure 10: CrAT Prefers Short Chain Acyl-CoAs. 
CrAT enzyme activity was measured with 0.45 mM acyl-CoA substrates of various chain lengths 
and 5.0 mM L-carnitine using (A) purified CrAT from pigeon breast muscle, (B) lysates from 
primary human skeletal muscle myocytes (HSkMC) expressing recombinant rat CrAT and (C) 
isolated mitochondria from mouse gastrocnemius muscle (MG). (D) CrAT activity as a function of 
increasing carnitine concentration measured in the presence of 0.45mM acetyl-CoA. Results are 
expressed as percent of maximal CrAT activity.  Data represent means ± S.E. from 3-5 separate 
experiments.   
 
We next examined palmitoyl-CoA inhibition of CrAT activity using the 
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of 30.6 µM (Figure 11A), whereas the IC50s for rat and mouse CrAT measured in 
HSkMC lysates and isolated mitochondria were 178 µM and 65 µM, respectively 
(Figures 11B and E). Oleoyl-CoA inhibited CrAT activity in a similar manner (data 
not shown). In isolated mitochondria, 40-60 µM palmitoyl-CoA reduced the Vmax 
of CrAT by 11- 23% (Figure 11C).  Intersection of the double reciprocal 
(Lineweaver-Burk) plots occurred to the left of the vertical (1/v) axis (Figure 11D), 
reflecting a mixed model form of inhibition.  This result implies a combination of 
uncompetitive inhibition (inhibitor binds only to the enzyme-substrate complex) 
and competitive inhibition (inhibitor binds only in the absence of substrate). Thus, 
palmitoyl-CoA appears to bind CrAT regardless of whether short chain acyl-CoA 
substrate is already bound.  Interestingly however, the concentration of palmitoyl-
CoA necessary for half-maximal inhibition of CrAT increased from 12 µM to 65 
µM in the presence of low (0.05 mM) as compared to high (2 mM) carnitine 
concentrations (Figure 11E).  This implies that binding of carnitine to CrAT 
reduces its affinity for palmitoyl-CoA, suggesting that long chain acyl-CoAs 
function as more potent inhibitors of the enzyme when mitochondrial 
concentrations of free carnitine are low.  
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Figure 11: Long Chain Acyl-CoAs Inhibit CrAT Activity. 
CrAT activity as a function of increasing palmitoyl-CoA concentration was measured using (A) 
purified protein from pigeon breast, (B) isolated mitochondria from primary human skeletal 
myocytes (HSkMC) expressing recombinant rat CrAT and (C, D)  isolated mitochondria from 
mouse gastrocnemius muscle.  Assays in panels A, B and E were performed with 0.45 mM 
acetyl-CoA and 5 mM L-carnitine. (E) Palmitoyl-CoA inhibition of CrAT activity as a function of L-
carnitine concentration using isolated mitochondria from mouse gastrocnemius.  Data represent 
means ± S.E. from 3-5 separate experiments (A,B), or 5-8 animals per group (C-E).  
 
Lipid exposure and increased CPT1 activity reduced acetylcarnitine 
production in primary human skeletal myocytes.  We next sought to determine 
whether chronic exposure of muscle mitochondria to elevated fatty acids is 
sufficient to inhibit CrAT activity in an intact cellular system.  To this end, primary 
HSkMC were incubated with increasing doses of a 1:1 mixture of oleate:palmitate 
and short chain acylcarnitine profiles were used as a surrogate index of CrAT 
activity.  Additionally, to promote fatty acid influx into the mitochondrial matrix 
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where CrAT resides, HSkMC were also treated with recombinant adenovirus 
encoding rat CPT1b.   This experimental paradigm was designed to mimic both 
the lipid conditions and increased expression of CPT1b that are characteristic of 
obesity and diabetes (Zou et al. 2009).  
 
After 24 h exposure to fatty acids, control cells treated with rAd encoding 
β-galactosidase (β-gal) increased production of palmitoylcarnitine (C16), 3-
hydroxypalmitoylcarnitine (C16:OH) and lauroylcarnitine (C:12) in a dose-
dependent fashion (Figures 12A-C). The C12 and C16:OH carnitine species are 
generated as byproducts of beta-oxidation.  Thus, cellular accumulation of these 
intermediates is likely to reflect increased production of the respective acyl-CoA 
precursors within the mitochondrial compartment.  Compared to the rAD-β-gal 
control group, treatment of cells with rAd-CPT1b caused a 4 to 9-fold increase in 
cellular levels of palmitoylcarnitine (C16), the direct product of the enzyme. 
Overexpression of rAd-CPT1b also elevated most long and medium chain 
acylcarnitines, suggesting increased mitochondrial transport and catabolism of 
fatty acids (Figures 12A-C).  Since medium and long chain acylcarnitines are 
thought to be in equilibrium with their acyl-CoA counterparts, these results 
support the notion that lipid exposure, especially in combination with CPT1b 
overexpression, leads to a rise in the mitochondrial pool of long chain acyl-CoAs.  
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Figure 12: Fatty Acid Exposure and CPT1 Overexpression Decrease Short 
Chain Acylcarnitine Production in Human Skeletal Myocytes 
Acylcarnitine levels were measured in lysates prepared from primary human skeletal myocytes 
treated with recombinant adenovirus encoding β-galactosidase (filled bars) or rat carnitine 
palmitoyltransferase-b (CPT1b) (open bars).  Cells were treated with adenoviruses on 
differentiation day 3 and harvested on day 7 following 24 h exposure to 1% BSA alone or 
complexed with 100 or 500 µM 1:1 oleate:palmitate, along with 1 mM L-carnitine. Specific 
acylcarnitine species shown include, (A) palmitoylcarnitine (C16), (B) 3-hydroxypalmitoylcarnitine 
(C16:OH), (C) lauroylcarnitine (C12), (D) butyrylcarnitine (C4), (E) propionylcarnitine (C3), (F) 
acetylcarnitine (C2) and (G) free carnitine. (H) Cellular levels of free carnitine and acetylcarnitine 
were strongly correlated.   * p<0.05 fatty acid treatment vs. BSA control, # p<0.05 rAd-CPT1b vs. 
β-gal control virus.  
 
Interestingly, despite marked lipid-induced increases in long and medium 
chain acylcarnitines, a disparate pattern emerged for the short chain products of 
the CrAT reaction.  For example, cellular accumulation of butyrylcarnitine (C4) 
increased dose-dependently in the control cells but not the rAd-CPT1b treated 
group.  On the contrary, conditions of high lipid exposure (500 µM O:P) caused 
C4 levels to decrease 50% in the CPT1b overexpressing cells as compared to 
controls (Figure 12D). Moreover, fatty acid exposure resulted in a dose-
dependent decrease in both propionylcarnitine (C3) and acetylcarnitine; and this 
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effect was exacerbated by CPT1b overexpression (Figure 12E-G).  A nearly 
identical pattern emerged when we measured acylcarnitine efflux into the culture 
medium during the same 24 h period of lipid exposure (Figure 13).  Interestingly, 
despite ample provision of extracellular carnitine (1 mM), intracellular content of 
free carnitine declined in response to lipid exposure, particularly in the rAd-
CPT1b group.  Also noteworthy, cellular concentrations of free carnitine 
correlated strongly with acetylcarnitine (Figure 12H) but not LCAC (not shown).  
These observations are consistent with the notion that lipid exposure 
antagonizes CrAT activity, not only by increasing mitochondrial concentrations of 
long chain acyl-CoAs but also by reducing availability of free carnitine within the 
mitochondrial matrix (Figure 14). 
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Figure 13: Fatty Acid Exposure and CPT1 Overexpression Decrease Short 
Chain Acylcarnitine Efflux from Human Skeletal Myocytes.   
Acylcarnitine levels were measured in culture media from primary human skeletal myocytes 
treated with recombinant adenovirus encoding β-galactosidase (filled bars) or rat carnitine 
palmitoyltransferase-β (CPT-1β) (open bars).  Cells were treated with adenoviruses on 
differentiation day 3 and harvested on day 7 following 24 h exposure to 1% BSA alone or 
complexed with 100 or 500 µM 1:1 oleate:palmitate, along with 1 mM L-carnitine. Specific 
acylcarnitine species shown include, (A) palmitoylcarnitine (C16), (B) 3-hydroxypalmitoylcarnitine 
(C16:OH), (C) lauroylcarnitine (C12), (D) butyrylcarnitine (C4), (E) propionylcarnitine (C3) and (F) 
acetylcarnitine (C2).  * p<0.05 fatty acid treatment vs. BSA control, # p<0.05 rAd-CPT1b vs. β-gal 
control virus.  
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Figure 14: Proposed Model of Lipid-Induced Inhibition of CrAT Activity.  
Fatty acid-derived long chain acyl-CoAs (LCACoA) cross the mitochondrial double membrane via 
the carnitine/acylcarnitine transport system.  After traversing the inner membrane through the 
action of carnitine acylcarnitine translocase (CT), the acylcarnitine products of CPT1 are 
converted back to LCACoAs by CPT2, thereby replenishing the matrix pool of free carnitine.  
Carnitine acetyltransferase (CrAT) converts short chain acyl-CoA (SCACoA) intermediates of fat, 
glucose and amino acid metabolism to short chain acylcarnitine (SCAC) metabolites that can 
efflux from the mitochondria when nutrient supply and catabolism exceeds flux through the 
tricarboxylic acid cycle (TCAC) and the electron transport system (ETS).  CrAT-mediated 
lowering of acetyl-CoA disinhibits pyruvate dehydrogenase (PDH), promoting glucose oxidation.   
Excessive formation and cellular efflux of LCAC depletes the matrix pool of free carnitine, thereby 
limiting CrAT activity.  Additionally, LCACoAs act as direct allosteric inhibitors of CrAT.  These 
mechanisms might serve to counter-regulate the activities of CrAT and PDH to spare glucose and 
promote beta-oxidation when lipids are plentiful.  
 
 
 
 
 
 
    
67  
3.4 Discussion:     
CrAT regulates the intra-mitochondrial pool of short chain acyl-CoAs.  
Because emerging evidence indicates this enzyme plays an essential role in 
regulating whole body glucose homeostasis, the present investigation sought to 
determine whether nutritional stresses that perturb metabolic control likewise 
alter CrAT expression and/or function.  Our study produced three major findings.  
First, in skeletal muscle and heart from obese rodents, tissue balance between 
acetylcarnitine and acetyl-CoA was disrupted in accord with reduced CrAT 
specific activity and elevated concentrations of long chain acyl-CoAs.  Second, 
we confirmed earlier reports that CrAT activity is potently inhibited by long chain 
acyl-CoAs.  Lastly, experiments in primary human myocytes showed that 
nutritional and genetic manipulations that promote fatty acid delivery to 
mitochondria caused a marked decline in cellular production and efflux of CrAT-
derived acylcarnitines.  In aggregate, these results suggest that CrAT function is 
compromised by chronic overnutrition, due at least in part to lipid-induced 
inhibition of enzyme activity.   
Chronic overnutrition results in accumulation of triacylglycerol and other 
lipid-derived metabolites in multiple tissues (Goodpaster and Kelley 2002, Muoio 
and Newgard 2008, Haqq et al. 2005). Consistent with these reports, the current 
study observed an increase in medium and long chain acyl-CoA metabolites in 
obese and diabetic rodents. Because β-oxidation is a rich source of short chain 
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acyl-CoAs, and because CrAT acts on acetyl-CoA derived from both glucose and 
fat catabolism (Muoio et al. 2012, Uziel et al. 1988), we anticipated that muscle 
acetyl-CoA and acetylcarnitine concentrations would rise in concert with long 
chain metabolites during periods of nutrient surplus. Instead, muscle 
acetylcarnitine levels remain unchanged or diminished while acetyl-CoA levels 
tended to increase (table 2). The corresponding decline in the 
acetylcarnitine/acetyl-CoA ratio was accompanied by decreased CrAT specific 
activity in each of the three models of obesity examined in this study (Figure 7-9). 
CrAT catalyzes the reversible reaction between short chain acyl-CoA and 
acylcarnitine with an equilibrium constant of 1.5–1.8 (Farrell et al. 1984, Pieklik 
and Guynn 1975). Therefore, enzyme activity has long been thought to be 
regulated by substrate/product concentrations within the mitochondrial matrix. 
However, we found that obesity and diabetes lowered CrAT specific activity at a 
post-translational level. Because early studies showed that LCACoAs can inhibit 
purified preparations of pigeon, rat and bovine CrAT (Chase et al. 1967, Huckle 
et al. 1983, Mittal et al. 1980), we assessed this form of regulation in a more 
native enzyme environment. Using isolated muscle mitochondria and muscle cell 
lysates, we found that palmitoyl-CoA acts as a potent inhibitor of CrAT activity 
with an IC50 of 12-65 µM. Likewise, fatty acid exposure on HSkMC resulted in 
decreased cellular production and efflux of short chain acylcarnitine species, 
especially when CPT1b was overexpressed. Importantly, fatty acid exposure and 
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or CPT1b overexpression resulted in diminished levels of CrAT-derived 
substrates only, with medium and long chain acylcarnitines changing in the 
opposite direction (Figure 13).  In aggregate, these findings support the 
hypothesis that accumulation of long chain acyl-CoAs leads to a reduction in 
CrAT activity. Though the foregoing in vitro assays point to allosteric inhibition as 
a potential mode of regulation, CrAT activity might alternatively be regulated via 
covalent modification. Protein acylation is a post translational form of enzyme 
regulation caused by reversible binding of an acyl-CoA group to one or more 
cysteine residues. Acylation regulates multiple enzymes involved in glucose 
metabolism including GAPDH (Yang et al. 2005) and phosphofructokinase-1 
(Jenkins et al. 2011). Once acylated, these enzymes have decreased activity 
leading to a decline in glucose metabolism, supporting the Randle hypothesis or 
the lipid-mediated lowering of glucose oxidation (Randle et al. 1963). The 
mechanism by which acylation occurs is not clear. Acylation can result from the 
enzymatic action of palmitoyl acyltransferase (Dunphy et al. 1996). However, 
many proteins have been shown to be autoacylated, or to spontaneously bind an 
acyl group in a concentration-dependent manner. These proteins include actin 
(Bano et al. 1998), the G protein α subunit (Duncan et al. 1996), tubulin (Wolff et 
al. 2000), rhodopsin (Veit et al. 1998), SNAP-25 (Veit et al. 2000), and many 
others. Further investigation is necessary to determine if CrAT might be 
regulated in this way. 
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Data herein demonstrate that the palmitoyl-CoA-mediated CrAT inhibition 
was a non-competitive or mixed-model interaction, in agreement with findings in 
bovine spermatozoa (Huckle et al. 1983). This finding is reminiscent of the 
interaction between CPT1 and its inhibitor, malonyl-CoA. High carnitine appears 
to compete with this inhibition (Lopez-Vinas et al. 2007), defending enzyme 
activity. Because CPT1 and CrAT share similar carnitine binding motifs (Jogl et 
al. 2004), these data support the notion that carnitine acyltransferases are 
susceptible to heightened inhibition when local carnitine concentrations fall. This 
observation is particularly relevant to obesity, diabetes and other conditions of 
carnitine insufficiency (Noland et al. 2009, De Palo et al. 1981, Soltesz et al. 
1983, Winter et al. 1989, Pregant et al. 1991, Tamamogullari et al. 1999, 
Poorabbas et al. 2007, Okudaira et al. 2001, Longo et al. 2006, Tein et al. 2003). 
Moreover, the finding that lipid-induced accumulation of long chain acylcarnitines 
was accompanied by a decrease in free carnitine and short chain acylcarnitine 
species suggests the possibility that the mitochondrial carnitine pool may be 
more prone to depletion than other compartments. Though regulation of carnitine 
between intra- and extramitochondrial compartments is poorly understood, CPT1 
may gain first access to free carnitine because of its location on the outer 
mitochondrial membrane. Persistent production and efflux of LCACs could 
compromise the intramitochondrial carnitine pool. Therefore, LCAC may 
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sequester free carnitine away from the CrAT reaction without limiting CPT1 
activity or fat oxidation.   
Importantly, evidence suggests that reduced CrAT activity might impact 
energy metabolism at a physiological level. Recent studies determined that 
muscle-specific CrAT deficiency disrupts whole body glucose homeostasis 
(Muoio et al. 2012). The glucose intolerant phenotype of CrATM-/- mice was 
coupled with impairments in the fasted to fed transition and a marked preference 
for fat oxidation. The mechanism linking CrAT to glucose oxidation could be due 
in part to CrAT production of acetylcarnitine, which is thought to relieve the 
acetyl-CoA-mediated inhibition of pyruvate dehydrogenase (PDH). Acetyl-CoA 
has been shown to stimulate pyruvate dehydrogenase kinases (PDKs), and to 
directly bind to the PDH complex, thereby diminishing its activity (Sugden and 
Holness 2003). In support of this model, muscle-specific deletion of CrAT 
resulted in complete loss of carnitine-stimulated PDH activity (Muoio et al.2012).  
Thus persistent inhibition of CrAT would be predicted to lower PDH activity, 
thereby inhibiting glucose disposal, both of which are commonly observed in 
obese rodents and humans (Randle et al. 1994, Sugden et al. 1995, Putman et 
al. 1993, Mondon et al. 1992). Further supporting the physiological role of CrAT 
deficiency in energy metabolism are the findings that carnitine supplementation 
improved insulin sensitivity and whole body glucose oxidation (Noland et al. 
2009, Powers et al. 2007). These positive effects on glucose metabolism were 
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associated with robust increases in circulating and urinary acetylcarnitine 
concentrations coupled with elevated PDH activity. Moreover, adenovirus-
mediated overexpression of CrAT in primary human skeletal muscle myocytes 
increased both acetylcarnitine efflux and glucose uptake (Muoio et al. 2012, 
Noland et al. 2009). Taken together, these data support the idea that deficiencies 
in CrAT activity exacerbate obesity-related metabolic derangements. 
Lastly, we consider the biological advantage of diminished CrAT activity 
when long chain acyl-CoA concentrations are high. Because recent studies have 
demonstrated that CrAT facilitates PDH activity and glucose oxidation (Muoio et 
al. 2012), we hypothesize this model might contribute to the glucose-fatty acid 
cycle described by Randle and colleagues, 1963. These studies propose that 
lipid-derived acetyl-CoA inhibits PDH activity and glucose oxidation (Randle et al. 
1963). CrAT opposes the Randle cycle by lowering acetyl-CoA, thereby 
increasing flux through PDH and glucose metabolism (Muoio et al. 2012). 
Therefore, CrAT-mediated acetylcarnitine generation promotes the fasted-to-fed 
transition. We propose that lipid-induced antagonism of CrAT might serve to 
counter-regulate glucose oxidation during circumstances of lipid surplus (Figure 
14). Whereas this mode of regulation could provide a survival advantage during 
starvation, we suggest that overnutrition may cause perpetual inhibition of CrAT 
activity, leading to depressed PDH activity and glucose homeostasis. A better 
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understanding of the pathophysiological implications of reduced CrAT activity 
awaits future investigation. 
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4 Carnitine Acetyltransferase Offsets Energy Stress 
and Delays Muscle Fatigue During Strenuous 
Exercise 
4.1 Introduction  
Habitual exercise not only improves physical fitness and muscle strength, 
but also promotes metabolic health and mitigates a wide-range of medical 
conditions (Gordon et al. 2009, Hafer-Macko et al. 2008, Hoehner et al. 2011, 
Ingram and Visovsky 2007, Young 1995).  Importantly however, aging and other 
chronic disorders are often accompanied by exercise intolerance, leading to a 
vicious cycle of inactivity and accelerated cardiometabolic decay.  In light of an 
aging population and the growing worldwide prevalence of metabolic disease, 
efforts to understand and modify exercise fatigue have become increasingly 
relevant to global health.   
At the most fundamental level, exercise tolerance depends on the ability of 
working muscles to resynthesize ATP at a pace that matches the costs of 
contractile activity.  Sustained regeneration of ATP is driven principally by 
mitochondrial oxidative phosphorylation (OXPHOS), a less powerful but more 
efficient and higher capacity system than glycolysis.  Whereas muscle 
mitochondrial content and respiratory capacity are well recognized determinants 
of exercise tolerance, several studies have shown that performance during both 
short and long term activities can also be influenced by the degree to which rates 
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of OXPHOS lag during the first several minutes of exercise and/or during 
stepwise increments in workload (Bangsbo et al. 2000, Howlett et al. 1998, 
Richardson et al. 1999, Tschakovsky et al. 1999).  This phenomenon of “oxygen 
deficit” is measured as a transient mismatch between increased energy 
expenditure and estimated rates of OXPHOS assessed by whole body VO2 
kinetics.  The debt incurred during these transitions is paid in large part by 
anaerobic glycolysis at the expense of lactate accumulation and accelerated 
glycogen depletion, both of which weigh negatively on muscle energy economy 
and performance.  
Rapid adjustments in the rate of OXPHOS depend on availability of 
oxygen as the final electron acceptor and a steady supply of electron donors in 
the form of NADH and FADH2.  Two general theories have been proposed to 
account for the foregoing lag in oxygen consumption during abrupt increases in 
exercise intensity.  The first suggests a limitation at the level of oxygen delivery 
to electron transport chain (ETC), whereas an alternative view proposes deficits 
in acetyl group availability, also referred to as metabolic inertia.  Acetyl-CoA 
holds a prominent position in exercise bioenergetics as the two carbon 
intermediate of glucose, fatty acid and amino acid catabolism.  Because acetyl-
CoA fuels the tricarboxylic acid (TCA) cycle, the main source of the reducing 
equivalents that drive OXPHOS, a deficit in acetyl-CoA supply would be 
predicted to limit the rate of oxidative ATP production.     
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Although limitations in oxygen and carbon supply are widely viewed as co-
contributors to oxygen deficit (Greenhaff et al. 2002, Knight et al. 1993, 
Richardson et al. 1995), the metabolic inertia theory draws attention to nutritional 
maneuvers that might augment the provision of specific acetyl group precursors.  
Relevant to this idea is emergent evidence that mitochondrial acetyl-CoA balance 
can be nutritionally regulated via the carnitine-dependent enzyme, carnitine 
acetyltransferase (CrAT) (Muoio et al. 2012).  This enzyme, which is highly 
enriched in muscle and heart (Noland et al. 2009), converts acetyl-CoA and other 
short chain acyl-CoAs to their membrane permeant acylcarnitine counterparts, 
thereby permitting mitochondrial and tissue efflux of excess carbons. Dietary 
supplementation with L-carnitine promotes net export of acetylcarnitine, which is 
accompanied by enhanced glucose tolerance when administered to obese 
rodents and humans (Noland et al. 2009).  These findings raised the question of 
why muscle tissues express such high amounts of an enzyme that essentially 
siphons acetyl-CoA from the TCA cycle.  The answer probably relates to the 
freely reversible nature of CrAT, which interconverts acetyl-CoA and 
acetylcarnitine with an equilibrium constant of ~1.5 (Farrell et al. 1984, Pieklik et 
al. 1975).  Thus, in theory, CrAT acts to buffer the mitochondrial pool of acyl-
CoA, which implies an important role for this enzyme in offsetting acetyl group 
deficit during transitions from low to high energy demand.  Although a number of 
studies have reported that both intramuscular and circulating levels of 
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acetylcarnitine increase during exercise (Sahlin et al. 1990, Hiatt et al. 1989, 
Putman et al. 1993, Watt et al. 2002), suggesting elevated flux through the CrAT 
reaction, the physiological relevance of these observations have remained 
uncertain.  Herein, we examined the impact of skeletal muscle-specific CrAT 
deficiency on muscle bioenergetics, acetyl group balance and exercise 
performance.  Our findings not only establish an important role for CrAT in 
regulating muscle energy economy during contraction, but also suggest that 
nutritional and/or pharmacological strategies aimed at promoting CrAT activity 
could prove useful for delaying muscle fatigue and combatting exercise 
intolerance. 
4.2 Materials and Methods: 
Animals: Animal studies were approved by the Duke University Institutional 
Animal Care and Use Committee. Mice were group housed and allowed ad 
libitum access to water and standard chow (Purina Rodent Chow no. 5015, 
Purina Mills, St. Louis, MO, USA). Mice were randomly selected to receive two 
weeks of supplementation with pH-neutralized drinking water containing 0 or 1 
mg/ml L-carnitine. Mice were anesthetized using an intraperitoneal injection of 
Nembutal with the dose of 100 mg/kg body weight. Tissue samples were frozen 
in liquid nitrogen and stored at -80oC. Tissues were ground into powder and 
processed in CelLytic buffer (Sigma Chemicals, St. Louis, MO) by freeze 
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fracturing three times and sonication at five times one second pulses on setting 
five. 
 
Mitochondrial Isolation: Skeletal muscle mitochondria were prepared according to 
(Noland et al. 2009). 
 
Carnitine acetyltransferase activity: CrAT activity was assessed according to 
(Muoio et al. 2012) and (Seiler et al. 2013). 
 
Western blots: Protein was isolated using CelLytic lysis buffer (Sigma Chemicals, 
St. Louis, MO). A bicinchoninic acid (BCA) kit (Sigma Chemicals, St. Louis, MO) 
was used to quantify protein. Protein (50µg from cell/tissue lysates) was 
separated by SDS-PAGE, transferred to nitrocellulose, and incubated with 
antibodies prepared with fish gelatin blocking buffer (0.5% fish gelatin, 2% 
10xPBS, 1 mg/ml casein and 15 mM NaN3). IgG-congugated AlexFluor 
fluorescent secondary antibodies (Invitrogen) were used with the Li-COR (Li-
COR Biosciences) to visualize bands. Protein expression was normalized to total 
protein as determined by MemCode staining (Thermo Scientific). The primary 
CrAT antibody was a generous gift from the laboratory of Dr. Fausto Hegardt. 
 
    
79  
Metabolite Analysis:  Tissue and plasma samples were processed and analysed 
by the Sarah W. Stedman Nutrition and Metabolism metabolomics/biomarker 
core laboratory.  Acylcarnitine measurements were made using flow injection 
tandem mass spectrometry and sample preparation methods described in (An et 
al. 2004) and (Haqq et al. 2005). Acyl-CoA esters were analyzed using a method 
based on a previously published report (Magnes et al. 2005) which relies on the 
extraction procedure described by (Deutsch et al. 1994).  The CoAs were further 
purified by solid phase extraction as described by (Minkler et al. 2008). 
Nucleotides were measured based on a previously reported method (Cordell et 
al. 2008). Chromatographic separations were performed using an Agilent 
Technologies (Santa Clara, CA) 1200 HPLC system and a Chromolith 
FastGradient RP-18e 50-2mm column (EMD Millipore, Billerica, MA, USA).   
 
Phosphocreatine Content: PCr and creatine analysis was done according to (Hu 
1975) and (Harris et al. 1974).  
 
Glycogen Content: Glycogen was assessed using approximately 20 mg of 
powdered skeletal muscle. 0.5 ml of 1 N HCl was added to the tissue in a 2.0-ml 
screw top tube and homogenized at 25K RPM for 30 seconds. The samples were 
then boiled for 90 minutes. The tubes were cooled to room temperature and 0.5 
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ml of 1 N NaOH was added. Glycogen content was assessed in the samples at 
340nm after addition of glucose assay reagent (Sigma).  
 
Lactate: Lactate was assessed at 340 nm. Lactate assay buffer consisted of 175 
mM hydrazide sulfate, 68 mM glycine, 2.9 mM EDTA, and 11.3 mM NAD+, pH 
9.5. Lactate standard (Sigma) was made up at 3, 1.5, 0.75, 0.375 and 0.1875 
mM. 20uL sample or standard were added with 200 uL assay buffer. Background 
absorbance was measured. 10 uL LDH enzyme (Sigma), made up at 500 
units/ml in water, was then added rapidly and absorbance was monitored for 60 
minutes. Upon kinetic plateau, final absorbance was taken. Lactate was 
determined according to the standard curve.  
 
Exercise Studies: Because of the inherent subjectivity of treadmill running to 
exhaustion, exercise studies were carried out in a blind fashion. Before exercise 
testing, three month old mice were acclimated to the treadmill for three days prior 
to the study. Acclimation consisted of a three minute run with one minute at each 
of the first three speeds in the respective protocol being tested. Exhaustion was 
defined as remaining on the shock grid for more than 10 seconds with nudging. 
Endurance: Endurance exercise was analyzed at a fixed slope of 10º. Mice 
began running at 8 m/min. Treadmill speed was increased 2 m/min every 15 
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minutes until 16 m/min was attained. At this point, mice were held at a consistent 
speed until exhaustion.  
Endurance with High Intensity Ramping: The transition from endurance to high 
intensity running was completed with a fixed slope of 10º. Similar to the 
endurance protocol described above, mice began running at 8 m/min and 
increased 2 m/min every 15 minutes for 1 hour total. After the initial hour, the 
mice were transitioned into a higher intensity exercise with 1 minute at 20 m/min, 
then 10 minutes at 23 m/min, with an increase of 3.5 m/min every 10 min until 
exhaustion. Data presented represent the ramping up period only. 
High Intensity: Exercise capacity during high intensity running was determined 
using an enclosed treadmill (Columbus instruments), attached to the 
Comprehensive Laboratory Animal Monitoring System (CLAMS) with a fixed 
incline of 10º. Mice began running at 14 m/min and increasing speed 3 m/min 
every 3 minutes until exhaustion. Measurements were collected every 30 
seconds during which air flow was set to 0.6 l/min. 
 
Ex-vivo muscle Stimulation and Acetylcarnitine Oxidation: Braided silk suture 
loops were attached to muscle tendons and excised from the mouse. Muscles 
were placed in pre-warmed KHB buffer (pH 7.4) which contained (in mmol/l) 118 
NaCl, 4.7 KCl, 2.52 CaCl2, 1.64 MgSO4, 24.88 NaCO3, 1.18 KH2PO4, 5.55 
glucose and 2.0 Na-pyruvate. After placement in a Radnoti 2 mL tissue bath 
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system, muscles were tensed to 1 gram and allowed to relax for 15 minutes. 
Muscles were then re-tensed to 1 gram and allowed to rest 5 minutes. This re-
tense/5 minute rest was repeated three times before initiation of stimulation. KHB 
buffer was used in muscle transport and tensing, while low glucose KHB (+2mM 
glucose, no pyruvate) was used during stimulation. The following stimulation 
protocol was used unless otherwise stated: stimulation rate: 60 pps, delay: 2000 
ms, duration: 300 ms, volts: 20 per chamber. O2 flow and temperature (25ºC) 
were kept constant throughout stretching and stimulation. Acetylcarnitine 
(Sigma), was made up at 1 M in H2O and added at a final concentration of 5 mM 
to stimulating muscles 30 seconds after initiation of contraction. This allowed for 
normalization of contracting muscles prior to acetylcarnitine addition. 
Acetylcarnitine oxidation was assessed by capturing media 14CO2 from 200 µM 
[1-14C]acetylcarnitine (ARC 1615) during rest or stimulation. Oxidation studies 
were done in low glucose KHB buffer with 3 mg/mL HEPES added. 
 
Statistics: JMP software version 7.0 (SAS Institute, Cary, NC) was used to 
perform multivariate correlation analyses of metabolites. Other statistical 
analyses were performed using SigmaStat (SysStat Software, Inc., Point 
Richmond, CA) or the Microsoft Excel statistical package. Within-group 
responses to experimental manipulations were evaluated using a paired t test, 
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where appropriate. All data are presented as mean S.E., and the level of 
significance was established a priori at p less than or equal to 0.05. 
 
4.3 Results  
Skeletal Muscle is a Primary Site of CrAT Activity. To characterize the 
relationship between CrAT and muscle function we first examined the fiber type 
distribution of the enzyme as well as its regulation in response to exercise.  In 
general, CrAT protein abundance was highest in the most oxidative/red muscles 
as compared to those comprised of a more glycolytic/white fiber types (Figure 
15A).  This expression pattern was only partly attributable to total mitochondrial 
content, as CrAT abundance was also dissimilar among isolated mitochondria 
preparations harvested from different muscles (Figure 15B).  Interestingly, 
mitochondrial abundance of CrAT tracked most closely with muscle enrichment 
of type IIa (intermediate) rather than type I (purely oxidative) myofibers.  Skeletal 
muscle mRNA levels of CrAT increased 4-fold in response to an acute 90 minute 
mid-intensity exercise bout (Figure 15C).  This was evident immediately after and 
up to 24 h after exercise as compared to the rested controls.  Likewise, 
genetically-engineered overexpression of the exercise-inducible transcriptional 
co-activator, PGC1α, increased crat gene expression in muscles from MCK-
PGC1α transgenic mice (Figure 15D) and in primary human skeletal myocytes 
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grown in culture (Figure 15E).  In aggregate, these results point to a role for CrAT 
in meeting the energetic needs of exercising muscles.   
To further explore the functional relevance of CrAT, we used the Lox-
P/Cre system described in Experimental Procedures to generate mice lacking 
crat specifically in skeletal muscle (CrATSM-/-).  This strategy resulted in 80-90% 
loss of CrAT activity in skeletal muscles without affecting that in heart (Figure 
15F-G). Interestingly, muscle quantities of acetylcarnitine, the principal product of 
CrAT, were only 27% lower in CrATSM-/- as compared to control mice (Figure 
15H), indicating that other tissues contribute to the skeletal muscle pool of this 
metabolite.  As predicted, CrAT deficiency was accompanied by a 1.5 fold 
increase in muscle concentrations of acetyl-CoA (Figure 15H).  
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Figure 15: Tissue-Specific Targeting of CrAT Activity 
CrAT protein abundance was determined in three month old rat  heart, red quad (RQ), red 
gastroc (RG), tibialis anterior (TA), soleus (SOL), planaris (Plant), white gastroc (WG), white quad 
(WQ), EDL and liver tissue homogenates (A) and isolated mitochondria (B). CrAT mRNA 
expression normalized to 18S was determined (C) in mouse gastrocnemius muscle at rest and 15 
minutes, 3 hours and 24 hours after a 90 minute exercise bout (D) in gastrocnemius 
homogenates from MCK-PGC1α transgenic and wild type (WT) control mice and (E) in primary 
human skeletal myocytes treated with recombinant adenovirus encoding β-galactosidase or rat 
PGC1α. Tissue-specific CrAT deletion was confirmed by analyzing CrAT protein (F) and enzyme 
activity (G) in multiple tissues (n = 3-6/group). Acetylcarnitine and acetyl-CoA in quadricep 
muscles were measured by mass spectrometry (H; n = 6/group). * Genotype effect (p<0.05). 
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Skeletal muscle-specific loss of CrAT compromised exercise performance 
despite increased fat oxidation. To test the impact of CrAT deficiency on exercise 
performance, CrATSM-/- and littermate controls were subjected to two different 
treadmill protocols (Figure 16A), both designed to challenge the capacity of the 
muscle to cope with several abrupt increments in energy demand.  The first was 
an endurance protocol with high intensity ramping during the latter half of the run.  
Time and distanced to exhaustion were decreased 18% and 29%, respectively in 
CrATSM-/- compared CrATfl/fl mice (Figure 16B).  During a second, higher intensity 
test the frequency and magnitude of the increments were increased and whole 
body respiration was monitored by indirect calorimetry.  Again, the CrATSM-/- mice 
performed poorly and completed only 66% of the distance covered by the control 
group (Figure 16C).  CrATSM-/- mice tended to have higher O2 consumption and 
lower CO2 production throughout the exercise, resulting in a lower average RER 
of 0.931compared to 0.992 in the CrATfl/fl controls (Figure 16D-F).  
Because a reduction in RER typically indicates a substrate shift in favor of 
fat oxidation, we proceeded to examine potential changes in β-oxidation potential 
using isolated muscle mitochondria.  Consistent with the whole body measures, 
maximal rates of palmitoylcarnitine-supported respiration were increased 38% in 
mitochondria harvested from CrAT deficient versus control muscles (Figure 16G).  
This was accompanied by 1.5-2.0-fold increases in muscle mRNA expression of 
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several β-oxidation enzymes, including CACT, CPT2, VLCAD and MCAD (Figure 
16H).   We suspect that this molecular remodeling of the β-oxidation machinery 
might be at least partly due to elevated levels of long chain acyl-CoAs (Muoio et 
al. 2012) and consequent activation of lipid-responsive transcription factors such 
as PPARα.  Collectively, these results revealed an atypical physiologic 
phenotype wherein enhanced capacity for fat oxidation was accompanied by 
reduced exercise tolerance. 
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Figure 16 CrAT Deficiency Compromises Exercise Performance Despite 
Increased Fat Oxidation 
12 week old mixed gender mice were run to exhaustion on two treadmill protocols described (A). 
Time and distance to exhaustion were determined during (B; n = 10/group) endurance exercise 
with high intensity ramping (data shown represent the ramping period only), and (C; n = 10/group) 
high intensity exercise. Indirect calorimetry was performed using an enclosed metabolic treadmill 
(Columbus Instruments) and VO2 (D), VCO2 (E), and respiratory exchange ratio (RER) were 
calculated (F; n = 10/group). State 3 mitochondrial respiration was determined in CrATfl/fl and 
CrATSM-/- gastrocnemius muscle using the Seahorse (Seahorse Bioscience) after the addition of 5 
mM malate, 1 mM carnitine and 5, 10 or 20 mM palmitoylcarnitine (G; n = 5/group). mRNA 
expression normalized to 18S was determined for carnitine palmitoyltransferase 1 (CPT1), 
carnitine acylcarnitine translocase (CACT), carnitine palmitoyltransferase 2 (CPT2), very long 
chain acyl-CoA dehydrogenase (VLCAD) and medium chain acyl-CoA dehydrogenase (MCAD) in 
CrATfl/fl and CrATSM-/- mouse gastrocnemius muscle (H; n = 6/group). * Genotype effect (p<0.05). 
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CrAT deficiency disrupted acetyl-CoA buffering capacity and exercise 
bioenergetics. To gain insight into the biochemical underpinnings of premature 
fatigue in CrATSM-/- mice, we evaluated muscle metabolite levels prior to 
exhaustion, using tissues collected from a second set of mice that were 
subjected to only 12 min of the high intensity treadmill running.  Metabolites were 
measured in muscles harvested 10 min or 1 h after exercise cessation and 
compared against those from rested controls.  In CrATfl/fl control mice, muscle 
concentrations of both acetylcarnitine (Figure 17A) and acetyl-CoA (Figure 17B) 
were remarkably stable at these time points.  By contrast, acetylcarnitine/acetyl-
CoA balance fluctuated dramatically in muscles from the CrATSM-/- mice (Figure 
17C).  Acetylcarnitine content in muscles from CrATSM-/- trended lower in the 
rested state (Figure 17A), but then increased to levels comparable to the control 
group during the post-exercise period.  Thus, exercise appeared to promote 
acetylcarnitine uptake from the circulation into working muscles.  Conversely, 
acetyl-CoA concentrations in muscles from CrATSM-/- vs. CrATfl/fl mice were 
elevated 2-fold at rest but then fell dramatically in response to exercise, implying 
a connection between acetyl group deficit and early fatigue.  In the CrATSM-/- 
mice, acetyl-CoA levels were partly restored during the 1 h recovery.   
Abrupt fluctuations in muscle energy demand are immediately buffered by 
PCr, which donates its high energy phosphoryl group to ADP in a freely 
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reversible phosphotransfer reaction catalyzed by creatine kinase (CK).  Muscle 
contraction favors CK flux in the forward direction to generate ATP and Cr, 
whereas the opposite holds true during exercise recovery.  Because the limited 
myocellular storage pools of PCr can provide for only a few seconds of maximal 
activity, continuous regeneration of PCr is critical to muscle performance and 
recovery.  Within 10 minutes of exercise cessation, the PCr pool in muscles from 
control mice was not only fully replenished but actually elevated compared to the 
rested state (Figure 17D).  This post-exercise overshoot is typical of a short 
duration, high intensity activity and indicative of robust cardiometabolic fitness 
(Korzeniewski et al. 2003, Korzeniewski et al. 2005, Sahlin et al. 1997, Meyer et 
al. 1994).  Notably, CrAT deficient muscles lost capacity to quickly stockpile PCr 
during the same recovery period (Figure 17D).   
Deficiencies in oxidative ATP production increase reliance on glycolysis 
and thus muscle glycogen reserves.  Interestingly, in the rested state muscle 
glycogen levels were elevated in CrATSM-/- mice, perhaps due to the foregoing 
shift in substrate selection (Figure 15E). However, despite elevated fat oxidation 
during the treadmill test (Figure 16E), exercise-induced depletion of muscle 
glycogen was 3.5-fold greater in the CrATSM-/- mice (Figure 17F).  Taken together, 
these findings provide strong support for the acetyl group deficit theory of muscle 
fatigue and offer the first conclusive evidence that CrAT is essential for 
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optimizing acetyl-CoA balance and muscle energy economy during and after 
exercise.       
 
Figure 17 Loss of Acetyl-CoA Buffering Capacity and Exercise 
Bioenergetics in CrATSM-/- Mice 
Quadricep muscle homogenates were harvested at rest, 10 minutes and one hour after a 12 
minute high intensity exercise. Tandem mass spectrometry was used to assess acetylcarnitine 
(A), acetyl-CoA (B), and the acetylcarnitine:acetyl-CoA ratio (C; n = 6/group). Phosphocreatine 
(PCr) (D), glycogen (E) and the exercise-induced glycogen depletion, calculated as % decreased 
from rest (F) were also determined (n = 5-8/group). * Genotype effect (p<0.05), ^ Exercise effect 
(p<0.05). 
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Exogenously supplied acetylcarnitine delayed fatigue and improved energy 
economy in a CrAT- dependent manner.  Results of the exercise tolerance 
studies suggested that CrAT-derived acetylcarnitine supports mitochondrial 
respiration when supply of acetyl-CoA from other fuel sources is limiting.  This 
hypothesis was subsequently confirmed in isolated mitochondria, which 
maintained high rates of acetylcarnitine-supported respiration in a CrAT-
dependent manner (Figure 18A).  Also noteworthy, acetylcarnitine permitted 
higher rates of respiration than palmitoylcarnitine, regardless of whether the two 
substrates we evaluated separately (Figure 18B) or in combination (Figure 18C).  
Results presented in Figure 17A suggested that exercise stimulates 
muscle acetylcarnitine uptake.  To test this possibility we used a muscle 
incubation bath system to examine contraction-induced changes in the oxidation 
rates of exogenously supplied [14C]acetylcarnitine in isolated soleus and EDL. As 
predicted, electrical stimulation applied during a 10 min incubation caused a 
marked 10-fold increase in acetylcarnitine catabolism to [14C]CO2 as compared to 
rested/unstimulated EDL muscles (Figure 18D).  This outcome was fully 
dependent on CrAT activity.  Moreover, in control muscles, provision of 5 mM 
acetylcarnitine enhanced force generation and delayed fatigue, such that time to 
half maximal force generation increased from 70 to 106 seconds (Figure 18E).  
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By contrast, acetylcarnitine had no effect on the force-fatigue properties of EDL 
from CrATSM-/- mice (Figure 18F).   
We then repeated these experiments and assessed muscle energy charge 
after four minutes of contraction, prior to fatigue.  As expected, pilot experiments 
performed with control mice confirmed robust contraction-induced shifts in 
muscle content of high energy phosphagens (Table 3).  In control but not CrAT-
deficient muscles, exogenously supplied acetylcarnitine defended the muscle 
PCr pool, resulting in a near two-fold increase in the post-contraction PCr/Cr ratio 
(Figure 18G).  In addition to the CK reaction, adenylate kinase also plays a key 
role in exercise bioenergetics by catalyzing phosphoryl group transfer from one 
ADP to another, thereby regenerating one ATP along with AMP.  The latter 
molecule can then be deaminated to produce IMP as a critical step in the 
adenine nucleotide cycle.  When acetylcarnitine was provided to control muscles, 
post-contraction levels of the foregoing adenine nucleotides reflected a favorable 
shift in energy charge.  Thus, acetylcarnitine lowered both the AMP/ATP and 
IMP/ATP ratios, indicative of improved metabolic efficiency. In support of this 
observation, lactate efflux declined after the addition of exogenous 
acetylcarnitine. By contrast, these same indices of energy stress were completely 
unresponsive to the acetylcarnitine treatment in muscles from the CrATSM-/- mice 
(Figure 18H-J).   
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Figure 18 Exogenously Supplied Acetylcarnitine Delayed Fatigue and 
Improved Energy Economy in a CrAT- Dependent Manner 
Seahorse measurements during state 3 respiration were conducted in gastrocnemius 
mitochondria (A; n = 5/group) after the addition of 1 mM carnitine and 1, 3.3 or 10 mM 
acetylcarnitine in CrATfl/fl and CrATSM-/- mice and (B; n = 5/group) at maximal palmitoylcarnitine 
(PC) and acetylcarnitine (AC) respiration in CrATfl/fl mice, determined to be 20 µM PC and 10 mM 
AC. The OROBOROS system was employed to determine state 3 respiration of permeabilized 
plantaris fiber bundles at maximal (100 µM) palmitoylcarnitine respiration ± 5 mM acetylcarnitine 
addition (C; n = 8/group). A Radnoti tissue bath system was used to determine 
[14C]Acetylcarnitine oxidation to CO2 in CrATfl/fl and CrATSM-/- EDL after a 4 and 10 minute 
stimulation (D; n = 4/group). Force generation and time to fatigue were determined ± 5 mM 
acetylcarnitine addition in CrATfl/fl (E) and CrATSM-/- (F) littermates (n = 6/group). EDL were flash 
frozen after a 4 minute stimulation ± 5mM acetylcarnitine and (G) the PCr/Creatine ratio, (H) 
AMP/ATP, (I) IMP/ATP and (J) media lactate were determined. * acetylcarnitine effect (p<0.05), # 
genotype effect (p<0.05). 
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Table 3: Contraction-Induced Changes in Muscle Content of High Energy 
Phosphagens 
EDL samples were harvested from control mice and flash frozen immediately after resting control 
or four minute stimulation. PCr and Cr content were analyzed and the PCr/Cr ratio was 
calculated. Liquid chromotagraphy-Mass spectrometry was used to assess ATP, ADP, AMP, IMP 
and the ratios ADP/ATP, AMP/ATP and IMP/ATP. Data are expressed as µmol/g tissue and 
represent means ± S.E. from 5-8 muscles per group. * p<0.05, rest vs. stimulated. 
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Carnitine supplementation enhanced exercise performance in control but not 
CrATSM-/- mice.  To determine whether the benefits of enhanced acetyl-group 
buffering capacity would take effect at a whole body level, we performed the 
same two graded treadmill tests described in Figure 16, but after two and four 
weeks of dietary L-carnitine supplementation.  Importantly, the genotype and 
treatment groups were blinded to the treadmill operators.  Consistent with 
previous reports (Noland et al. 2009, Makowski et al. 2009), administration of L-
carnitine in the drinking water increased circulating levels of free carnitine and 
acetylcarnitine by 30% and 20%, respectively, regardless of genotype (Figure 
19A-B).  In control mice, L-carnitine supplementation improved distance to 
exhaustion by 30% and 27% during the endurance with ramping and the high 
intensity regimens, respectively.  This carnitine-mediated improvement of 
exercise performance was absent in the CrATSM-/- mice (Figure 19C-D).  Serum 
levels of acetylcarnitine measured immediately after the second treadmill test 
were increased 34-38% in both carnitine supplemented groups (Figure 19E), 
while intramuscular levels of free, esterified and total carnitine levels were 
unchanged (Figure 19F). Thus, in line with results of the muscle incubation 
experiments (Figure 18E), increased supply of acetylcarnitine to working muscles 
was accompanied by enhanced exercise tolerance in CrATfl/fl mice but not 
CrATSM-/- counterparts.  In aggregate, these results support the idea that 
nutritional strategies aimed at increasing acetyl-CoA buffering capacity have the 
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potential to augment energy efficiency and delay muscle fatigue during strenuous 
physical activity.  
 
Figure 19: Acetylcarnitine Enhanced Exercise Performance in Control but 
Not CrATSM-/- Mice 
Mice were randomly selected to receive supplementation with pH-neutralized drinking water 
containing 0 or 1 mg/ml l-carnitine for two and four weeks. Tandem mass spectrometry was used 
to assess free carnitine (A) and acetylcarnitine (B) in blood spots taken from the tail vein. Time 
and distance to exhaustion were determined during (C; n = 6/group) endurance exercise with 
high intensity ramping (data shown represent the ramping up period only), and (D; n = 6) high 
intensity exercise. Plasma acetylcarnitine (E) and quad total carnitine (F; free carnitine + 
acetylcarnitine) were determined after a 90 minute endurance with ramping bout. * p<0.05 
carnitine effect, ^ genotype effect (p<0.05). 
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Figure 20: Proposed Role of CrAT in Mitochondrial Acetyl-CoA Buffering 
and Acetyl Group Transfer During Exercise 
Acetyl-CoA is the crucial catabolic intermediate that fuels the tricarboxylic acid (TCA) cycle, which 
in turn serves as the main source of reducing equivalents (NADH) that support oxidative 
regeneration of ATP by the electron transport chain (ETC). During transitions from low to high 
exercise workloads, TCA cycle flux must increase to keep pace with the high ATP demands of 
muscle contraction.  A shortfall in acetyl-CoA provision will force heavy reliance on substrate level 
phosphorylation, resulting in depletion of phosphocreatine (PCr) and muscle glycogen reserves, 
along with production of lactic acid and other deleterious metabolic byproducts.  CrAT functions to 
sustain high rates of oxidative ATP regeneration via two proposed mechanisms.  First, 
contraction-induced recycling and/or import of acetylcarnitine (AcCarn) supplies a readily 
available source of acetyl group donors to buffer transient deficits in rates of glucose, amino acid 
and fatty acid catabolism.  Secondly, CrAT permits rapid and efficient delivery of acetyl groups 
from their site of production to the TCA cycle (blue arrows).  By residing in close proximity to the 
various enzymatic sources of acetyl-CoA (e.g. pyruvate dehydrogenase (PDH) and ketothiolase 
(KT)), CrAT alleviates kinetic hindrances due to product inhibition while also regenerating 
essential cofactor (CoA) for continued catabolic flux.  Additionally, by acting as a conduit for 
acetyl group transfer, CrAT overcomes the thermodynamic inefficiencies of diffusional flux, which 
requires an energetically unfavorable gradient profile (black triangle).  This model of substrate 
transfer through a series of near-equilibrium reactions is conceptually analogous to the phospho-
energy transfer networks driven by the adenylate kinase and creatine kinase (CK) systems. 
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4.4 Discussion 
Previous studies have suggested that rapid adjustments in the rate of 
OXPHOS during transitions from low to higher workloads might be limited by a 
lag in enzyme activation, leading to transient deficits in metabolic flux and acetyl-
CoA production.  In the current investigation we hypothesized that the acetyl 
group buffering capacity of CrAT plays a critical role in mitigating and/or 
compensating for metabolic inertia.  Fitting with this prediction, we provide new 
and compelling evidence that CrAT activity influences acetyl-CoA balance, 
muscle bioenergetics and time to fatigue during intense exercise.  Muscle-
specific deletion of CrAT compromised muscle energy economy and contractile 
performance, whereas enhancement of acetyl-CoA buffering capacity via dietary 
L-carnitine supplementation improved exercise tolerance in a CrAT-dependent 
manner.  These findings are consistent with the acetyl group deficit theory of 
fatigue and suggest that strategies aimed at augmenting CrAT activity could have 
value as an ergogenic aid.   
Recent studies found that CrAT protein is most abundant in skeletal 
muscle and heart, tissues specifically designed for work (Noland et al. 2009). 
Moreover, in the present study we found that CrAT mRNA expression increases 
in response to acute exercise (Figure 15C). Together, these findings point to a 
role for CrAT in contraction. However, heretofore, experimental evidence to 
support this idea was lacking. Importantly, our study fills this gap with three major 
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findings.  First, we provide evidence that CrAT indeed has a critical role in 
strenuous exercise performance using a novel mouse model of CrAT skeletal 
muscle deficiency. Second, we used ex-vivo analysis to demonstrate that CrAT 
offsets the contraction-mediated acetyl-CoA deficit and maintains high rates of 
phosphocreatine (PCr) regeneration, thereby improving mitochondrial energetics 
and delaying fatigue.  Lastly, we demonstrated that supplementation with 
carnitine, a primary substrate for the CrAT reaction, improved exercise 
performance in CrATfl/fl but not CrATSM-/- mice. In aggregate, these results 
establish a critical role for CrAT in combatting contraction-induced energy stress 
and fatigue.  
 A growing literature has suggested that acetyl-CoA might be a 
limiting factor for mitochondrial ATP generation during exercise. This acetyl 
group deficit theory was driven by studies using dichloroacetate (DCA) to elevate 
acetyl group availability prior to and during contraction. DCA, a chemical 
compound that has been shown to combat PDH phosphorylation thereby 
activating the enzyme complex, drives pyruvate flux through PDH. The resulting 
expansion of the acetylcarnitine pool resulted in improved exercise performance 
and mitochondrial energetics (Howlett et al. 1999, Timmons et al. 1998, Timmons 
et al. 1996). Acetylcarnitine, the principal product of the CrAT reaction, makes up 
greater than 80% of the total acylcarnitine metabolite pool in skeletal muscle and 
plasma (Muoio et al. 2012). It has long been known that intense physical activity 
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dramatically induces skeletal muscle acetylcarnitine accumulation (Sahlin et al. 
1990, Hiatt et al. 1989, Putman et al. 1993). However, the physiological 
relevance of CrAT activity and acetylcarnitine efflux during exercise remains 
unknown. Data herein suggest that CrAT-mediated skeletal muscle uptake 
and/or production of acetylcarnitine might be an important component in 
exercise. We demonstrate that CrAT functions to offset the acetyl-CoA deficit 
during high intensity contraction. Indeed, CrAT deficiency resulted in a sharp 
decline in acetyl-CoA levels after exercise while acetylcarnitine followed the 
opposite pattern (Figure 17A-B). Intriguing is why CrAT is so important for 
maintaining acetyl-CoA balance during exercise.  
One possibility is that CrAT-mediated uptake of acetylcarnitine might 
provide an acetyl group donor for the TCA cycle. In support of this hypothesis, 
we demonstrated an accumulation in acetylcarnitine after exercise in CrAT 
deficient mice (Figure 17B). Further, we observed a rise in CrAT-dependent 
uptake and oxidation of acetylcarnitine during exercise (Figure 18D). These data 
suggest that skeletal muscle clears acetylcarnitine during work. CrAT-mediated 
mitochondrial acetylcarnitine consumption might also provide a kinetic advantage 
over alternate fuels. Thus acetylcarnitine might bypass the well-controlled multi-
step glycolysis and β-oxidative pathways during high energy demand, providing a 
rapid one-step substrate for the TCA cycle. In support of this hypothesis, 
exogenous acetylcarnitine enhanced force generation, delayed fatigue and offset 
    
102  
energy stress in CrATfl/fl but not CrATSM-/- muscles despite the presence of 2 mM 
glucose (Figure 18E-J). Furthermore, maximal palmitoylcarnitine-supported 
respiration in permeabilized muscle fibers could be further increased with the 
addition of 5 mM acetylcarnitine (Figure 18C). Conversely, acetylcarnitine did not 
have the same impact on maximal pyruvate-supported respiration (data not 
shown). However, factors limiting pyruvate production and/or diverting pyruvate 
into an anaplerotic substrate could dramatically reduce the pyruvate contribution 
to intramitochondrial acetyl-CoA during high intensity exercise. Despite evidence 
supporting this hypothesis, circulating acetylcarnitine, present in micromolar 
concentrations, accounts for less than 1% of the ATP generating potential of 
circulating glucose, which is present in millimolar concentrations. Thus, it is 
surprising that circulating acetylcarnitine could be a factor in skeletal muscle ATP 
generation.  
Therefore, we considered the possibility that intramuscular acetylcarnitine 
production might contribute a local acetyl group pool for ATP generation. We 
hypothesize that acetylcarnitine production in oxidative fibers might expand the 
carnitine pool to benefit glycolytic fibers within the same muscle tissue. During 
intense exercise, oxidative fibers reach maximal ATP generation well before 
glycolytic fibers and might begin to efflux a local pool of acetylcarnitine for 
glycolytic fiber consumption. CrAT protein is most abundant in oxidative skeletal 
muscle (Figure 15A) but mitochondrial CrAT tracked closely with type IIa, 
    
103  
intermediate fibers (Figure 15B). Therefore, inner-fiber cross talk within type IIa 
fibers might add to the acetyl group pool, though more work is needed to fully 
elucidate this mechanism.  
However, recent studies using magnetic resonance spectroscopy in 
working heart suggest a more sophisticated mechanism of action. Schroeder and 
colleagues observed that 50% of pyruvate-derived citrate cycled through 
acetylcarnitine before entry into the TCA cycle (Schroeder et al. 2012). 
Therefore, we considered the possibility that flux through the CrAT reaction might 
be thermodynamically advantageous during high intensity exercise. Thus cycling 
through CrAT could be critical for acetyl-CoA trafficking from PDH production into 
the TCA cycle. Because acetyl-CoA is a potent inhibitor of PDH activity (Sugden 
et al. 2003), CrAT might function to keep the concentration gradient in favor of 
acetyl-CoA production during exercise (Figure 20). This theory is reminiscent of 
the creatine kinase and adenylate kinase phosphotransfer reactions. The 
adenylate kinase reaction combines ADP to produce ATP and AMP. AMP is then 
degraded to IMP in order to keep the adenylate kinase reaction favoring the 
production of ATP. Likewise, the creatine kinase reaction is critical for the rapid 
and efficient trafficking of ATP from its production site in the mitochondria to the 
myofibrils during work. In this way, creatine kinase prevents sluggish ATP 
diffusion to contractile machinery and avoids feed-back inhibition of ATP 
production. In aggregate, exercise stimulation requires these coupled reactions 
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for the rapid and efficient transfer of energy. Likewise, we suggest the 
requirement of CrAT for acetyl group trafficking within the mitochondria.  
Carnitine supplementation in CrATfl/fl but not CrATSM-/- mice improved 
exercise performance (Figure 19), suggesting that expansion of the skeletal 
muscle carnitine pool during contraction might stimulate CrAT cycling.  However, 
though circulating carnitine and acetylcarnitine levels were elevated with 
exogenous carnitine provision, skeletal muscle levels remained unchanged 
(Figure 19E-F). We hypothesize that elevated carnitine uptake during contraction 
accounts for the stimulation in CrAT activity while exercise cessation results in 
metabolite efflux. In support of this hypothesis, data herein demonstrated a 
stimulation-induced rise in skeletal muscle acetylcarnitine influx and oxidation 
(Figure 18D). Furthermore, studies in skeletal muscle have shown a contraction-
mediated boost in carnitine uptake (Furuichi et al. 2012). Therefore, expansion of 
the muscle carnitine pool during exercise might stimulate CrAT activity, providing 
thermodynamically favorable acetyl-CoA trafficking.  
We propose the importance of CrAT-mediated acetyl-CoA buffering in 
disorders wherein exercise intolerance and fatigue lead to inactivity, such as in 
individuals with peripheral vascular disease (PVD), aging, ischemia and inborn 
errors of mitochondrial metabolism. Because exercise promotes metabolic health 
and improves a multitude of maladies, understanding and improving exercise 
tolerance and fatigue is critical for these patients. For example, PVD skeletal 
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muscle is associated with decreased work efficiency marked by excessive PCr 
use and blunted exercise capacity (Greiner et al. 2006). Similarly, aging skeletal 
muscle is associated with lowered PCr hydrolysis and diminished peak 
contractile force and ATP production (Tevald et al. 2009, Lanza et al. 2007, 
Campbell et al. 1991). This phenotype results in compromised exercise 
tolerance, leading to inactivity and accelerated cardiometabolic decay. Therefore, 
improved energy efficiency through stimulation of the CrAT reaction might be key 
for the treatment and prevention of exercise intolerance. In support of this 
hypothesis, provision of both carnitine and propionylcarnitine improved walking 
distance in PVD patients (Brevetti et al. 1992, Brevetti et al. 1988). These data 
suggest that strategies aimed at stimulating flux through the CrAT reaction could 
prove beneficial for promoting energy metabolism and delaying fatigue. 
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5 Conclusions and Future Directions: 
Data herein focused on the CrAT enzyme and its role in regulation of the 
intramitochondrial acetyl-CoA pool. We presented compelling evidence 
suggesting that maintenance of the acetyl-CoA pool is imperative for 
mitochondrial homeostasis. Chapter 3 summarized the negative consequences 
of acetyl-CoA overproduction and proposed the important role of CrAT in 
preventing accumulation of this metabolite. These data suggest that lipid induced 
inhibition of CrAT activity, resulting in a decrease in the skeletal muscle 
acetylcarnitine:acetyl-CoA ratio, contributes to insulin resistance. Alternatively, 
Chapter 4 suggested the deleterious effects of an acetyl-CoA deficit during 
exercise. These studies demonstrate a role for CrAT in acetyl-CoA buffering and 
provide insight into exercise physiology, potentially providing important 
implications for patients with muscle weakness and fatigue. In aggregate, these 
data suggest a critical role for CrAT as a regulator of mitochondrial acetyl-CoA. 
Because CrAT is highly involved in fine-tuning both acetyl-CoA accumulation and 
deficiency, a model we are just beginning to understand, it is likely that we have 
not yet fully elucidated its role in mitochondrial energetics. Moreover, it seems 
feasible that remaining questions about the regulation of CrAT activity will 
provide important insights into the pathogenesis of multiple disease states. 
Though progress has been made to understand the role of CrAT in metabolism, 
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many questions remain. The following sections contain an overview of several 
unanswered questions pertaining to the involvement of CrAT in mitochondrial 
homeostasis.  
5.1 Reactive Oxygen Species: 
Multiple studies have demonstrated an antagonistic role of fat load on 
insulin signaling and glucose uptake (Hirosumi et al. 2002 and Shulman et al. 
2000). These data suggest that impaired insulin action occurs by diverting fatty 
acids away from mitochondrial oxidation, leading to the buildup of lipid species 
capable of inhibiting insulin signaling. However, recent studies observed lipid-
induced derangements in substrate switching within isolated mitochondria 
(Noland et al. 2009, Koves et al. 2008), suggestive of a connection between 
mitochondrial bioenergetics and insulin action.  Genetic and nutritional models of 
obesity and diabetes led to excessive β-oxidation and metabolic inflexibility, while 
genetic inhibition of fat oxidation preserved glucose tolerance (Noland et al. 
2009, Koves et al. 2008, Koves et al. 2005). These studies suggest that 
derangements in mitochondrial metabolism might compromise insulin action, 
though the link between mitochondrial impairment and insulin signaling is poorly 
understood. Recent evidence suggests that insulin signaling may be negatively 
affected by mitochondrial-derived reactive oxygen species (ROS) formation 
(Bloch-Damti and Bashan 2005, Evans et al. 2005). ROS production has gained 
momentum as a factor in the development of insulin resistance (Anderson et al. 
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2007, St-Pierre et al. 2002). ROS have been shown to activate multiple serine 
kinases and transcription factors implicated in diminished insulin signaling 
(Bloch-Damti and Bashan 2005, Chakraborti and Chakraborti 1998). As 
previously described, ROS production is high when ATP demand is exceeded by 
electron flux into the ETC. This causes heightened backpressure on complex I, 
resulting in increased electron leak and ROS production (reviewed in Fisher-
Wellman and Neufer 2012, Muoio and Neufer 2012). ROS can then interact with 
glutathione, the primary redox buffer in the cell, shifting the ratio of reduced 
glutathione (GSH) to its oxidized counterpart (GSSH). Just four hours after a 
single meal high in fat, ROS emission more than doubled while a 50% reduction 
in the GSH/GSSG ratio was observed in rat skeletal muscle fiber bundles, owing 
to the sensitivity of complex I electron leak to the redox state. Moreover, 5 days 
of high fat diet resulted in a persistent oxidative environment due to sustained 
elevation in ROS. This shift in redox environment toward the oxidative state could 
provide a potential link between insulin resistance and mitochondrial ROS 
(Anderson et al. 2009). In support of this hypothesis, interventions that lowered 
mitochondrial ROS production were shown to preserve insulin action (Lee et al. 
2010, Hoehn et al. 2009, Anderson et al. 2009). Therefore, understanding the 
development and maintenance of ROS could provide critical information 
regarding the pathogenesis of insulin resistance.   
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Preliminary data suggests that CrAT might play a role in mitigating the 
production of ROS. We used confocal microscopy to establish that carnitine 
treatment reduced the production of ROS by 60% in human skeletal muscle cells 
(figure 21).  
 
Figure 21: Carnitine Mitigates Production of Reactive Oxygen Species in 
Cultured Myocytes  
Dichlorofluorescin diacetate (DCFDA) treated L6 cells were given 100uM carnitine during 
differentiation and 100µM buthionine sulfoximine (BSO) for 24 hours where indicated and imaged 
on a Leica SP5 confocal microscope. BSO selectively inhibits the synthesis of glutathione, which 
results in increased production of reactive oxygen species.  
 
These data suggest a possible link between heightened CrAT activity and 
reduced ROS production. Through its unique ability to efflux excess carbons, 
CrAT may alleviate mitochondrial stress in situations of high fuel load and low 
energy demand, such as during nutrient overload or immediately upon the 
cessation of exercise. Therefore, manipulations designed to stimulate CrAT 
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activity, such as carnitine supplementation, might reduce mitochondrial stress by 
re-routing short chain acyl-CoA surplus into carnitine esters.  
Strong evidence shows that mitochondrial ROS generation is increased 
immediately following contractile activity. Because ROS production is elevated 
when ATP demand is low (physical inactivity) but nutrient delivery is high 
(overfeeding or immediately post-exercise), we hypothesize a potential 
importance of the CrAT enzyme in relieving mitochondrial stress after 
contraction. Succinyl-CoA, which is uniquely positioned as the only acyl-CoA 
intermediate of the TCA cycle, also donates reducing equivalents into the ETC 
via succinate. We propose that cessation of exercise results in an abrupt drop in 
ATP production and electron transport while flux through the TCA cycle remains 
high. Therefore, increased succinate dehydrogenase-derived reducing 
equivalents have the potential to increase ROS production through backpressure 
on complex I. We have shown that CrAT acts preferentially on short chain acyl-
CoAs (Chapter 3). Because succinyl-CoA is a four carbon short chain acyl-CoA, 
we believe it to be a substrate for the CrAT reaction. In support of this 
hypothesis, recombinant adenovirus technology overexpressing CrAT in primary 
human skeletal muscle myocytes resulted in a 12 fold elevation in skeletal 
muscle succinylcarnitine (Figure 22A). Additionally, skeletal muscle specific CrAT 
deficiency resulted in a 50% reduction in succinylcarnitine metabolite levels at 
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rest, 10, and 60 minutes after a short term high intensity exercise bout (Figure 
22B).  
 
Figure 22: Manipulations in CrAT Alter Skeletal Muscle Succinylcarnitine 
Content  
Acylcarnitine levels were measured in primary human skeletal muscle cell lysate after treatment 
with B-gal control or rat CrAT overexpression adenovirus (A). CrAT skeletal muscle specific 
knockout mice (CrATSM-/-) were subjected to an 11 minute high intensity exercise bout. Data was 
collected at rest, immediately following exercise and 1 hour post exercise in CrATSM-/- compared 
to control mice (CrATfl/fl) (B). 
 
We hypothesize that CrAT plays a role in relieving the exercise-mediated 
build-up of succinyl-CoA by forming succinylcarnitine, thus reducing the 
production of ROS following an exercise bout. In support of this theory, we used 
metabolomic profiling to demonstrate that plasma levels of succinylcarnitine 
increased after a short term, high intensity exercise bout in wild type mice but not 
in mice with a skeletal muscle specific deletion of CrAT (figure 23).  
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Figure 23: CrAT Deficiency Alters Exercise-induced Changes in Circulating 
Levels of Succinylcarnitine  
Acylcarnitine levels were measured in CrATfl/fl and CrATSM-/- mice subjected to an 11 minute high 
intensity exercise bout. Blood was sampled at rest, immediately following exercise and 1 hour 
post-exercise.  
 
To definitively test the importance of CrAT in preventing ROS production, 
ROS indicators such as skeletal muscle glutathione levels, lipid peroxides, and 
protein carbonyls must be analyzed in CrAT skeletal muscle knock out and wild 
type littermates both before and after an exercise challenge. Additionally, ROS 
signaling pathways should be assessed via western blot analysis. Lastly, amplex 
red can be used to measure ROS generation in isolated skeletal muscle 
mitochondria from wild type and CrAT deficient mice. These studies will provide 
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novel insights into the role of CrAT in regulating the mitochondrial redox 
environment.  
5.2 Lysine Acetylation: 
Lysine acetylation, a reversible post-translational modification, has 
become increasingly recognized as a relevant link between fuel metabolism and 
mitochondrial stress. Sirtuins, a family of nicotinamide adenine dinucleotide 
(NAD+)-dependent protein deacetylases have been shown to regulate the 
acetylation state of several key metabolic enzymes. Seven sirtuins have been 
identified with varied compartmentalization. SIRT1, SIRT6 and SIRT7 are found 
in the nucleus, SIRT1 and SIRT2 in the cytoplasm and SIRT3-5 in the 
mitochondria (reviewed in Denu 2005). Within the mitochondria, SIRT3 appears 
to be the primary deacetylase, with no observable deacetylase activity of SIRT4 
or SIRT5. Robust mitochondrial hyperacetylation was observed in SIRT3 
knockout mice, while no change was obvious in knockouts of either SIRT4 or 
SIRT5 (Lombard et al. 2007). Interestingly, SIRT5 has been shown to drive 
mitochondrial desuccinylase and demalonylase activity (Du et al. 2011), while the 
primary role of SIRT4 is still under investigation. 
The NAD+ dependent activation of sirtuins suggests a link between 
deacetylase activity and the energy status of the cell. Supporting this hypothesis, 
an estimated 35% of mitochondrial proteins have shown to be acetylated, the 
majority of which are involved in energy metabolism (Anderson and Hirschey 
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2012). Moreover, greater than 50% of proteins involved in glucose, fatty acid, 
and amino acid oxidation as well as the TCA cycle and oxidative phosphorylation 
were found to be acetylated (Anderson and Hirschey 2012), highlighting the 
potential importance of mitochondrial acetylation state on fuel metabolism. Found 
to be highly expressed in metabolically active tissues such as liver, heart and 
oxidative skeletal muscle, SIRT3 activity is induced during fasting, caloric 
restriction, and exercise training (Palacios et al. 2009, reviewed in Nogueiras et 
al. 2012). These data imply a critical role for SIRT3 in stimulating mitochondrial 
fuel metabolism during low energy stress. On the other hand, SIRT3 knockout 
mice exhibited accelerated glucose intolerance with age and high fat diet (HFD), 
suggesting a link between aberrant SIRT3 activity and the metabolic syndrome 
(Hirschey et al. 2011). Interestingly, though an acute high fat diet induced SIRT3 
expression (Bao et al. 2010), chronic nutrient overload led to decreased SIRT3 
protein and mRNA in both liver (Hirschey et al. 2011, Bao et al. 2010) and 
skeletal muscle (Jing et al. 2011), resulting in mitochondrial hyperacetylation. 
The loss of SIRT3 seen in HFD-fed mice is thought to be driven by decreased 
activity of peroxisome proliferator-activated receptor-у coactivator 1α (PGC-1α), 
a transcriptional coactivator involved in energy metabolism which is suggested to 
target SIRT3 (Kong et al 2010, Hirschey et al 2011). In support of this 
hypothesis, acute HFD stimulated while chronic HFD compromised PGC-1α 
mRNA (Koves et al. 2005), similar to the observed nutritional regulation on 
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SIRT3. Furthermore, PGC-1α was shown to interact with the SIRT3 promoter 
(Kong et al. 2010), and exogenous PGC-1α rescued the HFD-induced loss in 
SIRT3 (Hirschey et al. 2011). 
While extensive research has gone into deacetylase activity through 
sirtuin action, little is known about mitochondrial acetylase activity. Abundance of 
acetyl-CoA, the common metabolic intermediate of glucose, fatty acid and amino 
acid oxidation, has been suggested to positively correlate with hyperacetylation 
(Hirschey et al. 2011, Schwer et al. 2009). In support of this hypothesis, we have 
shown a significant increase in skeletal muscle acetyl-CoA as a result of a 20 
week high fat diet (Chapter 3), which is consistent with decreased SIRT3 
abundance and elevated protein acetylation (Jing et al. 2011). However, the 
mechanism driving acetylation is not fully elucidated. Though mitochondrial 
acetyltransferases have not been identified, their activity could prove to be 
important in the regulation of mitochondrial acetylation state. Non-enzymatic 
acetylation has also been shown to occur in vitro on histones (Paik et al. 1970), 
suggesting the possibility that acetyl-CoA levels could drive either enzymatic or 
non-enzymatic acetylation.  
Because acetyl-CoA is the primary substrate for the CrAT reaction, we 
propose a role for CrAT in regulating mitochondrial acetylation. Recent studies 
have demonstrated that CrAT deficiency, shown to induce acetyl-CoA 
accumulation (Chapter 4), resulted in a glucose intolerant phenotype (Muoio et 
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al. 2012), likely due in part to persistent acetyl-CoA-mediated PDH inactivation. 
However, we propose CrAT ablation additionally leads to mitochondrial 
hyperacetylation driven by elevated acetyl-CoA, potentially further dysregulating 
metabolic flexibility. Moreover, because flux through the CrAT reaction is 
diminished in high fat diet and diabetic rodents, models with observed 
hyperacetylation (Chapter 3, Hirschey et al. 2011, Jing et al. 2011), we suggest a 
critical role for CrAT in governing acetyl-CoA levels when nutrient load exceeds 
energy demand. Therefore, we propose CrAT may function to promote metabolic 
flexibility and glucose tolerance through the efflux of carbon fuels, thereby 
curbing acetyl-CoA-mediated hyperacetylation.  
Preliminary data supporting this hypothesis has been generated by two 
postdoctoral fellows in the Muoio lab. Drs. Michael Davies and Lilja Kjalarsdottir 
found elevated mitochondrial acetylation in CrAT deficient skeletal muscle in 
mice fed a high fat diet (unpublished data). Further, proteomics screening 
resulted in an observed 14 hyperacetylated mitochondrial proteins in CrAT 
deficient skeletal muscle compared to wild type controls (unpublished data). 
These data suggest a role for CrAT in mitochondrial acetylation state. However, 
more work is required to elicit a mechanism. Use of the CrAT skeletal muscle-
specific knockout mouse coupled with site directed mutagenesis will potentially 
uncover interactions between CrAT regulation and enzyme control in the 
mitochondria. Additionally, these tools could become important in identifying 
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acetylation-targeted proteins that may be independent of SIRT3 regulation. 
These studies will improve our understanding of interactions between acetylation 
state and the metabolic syndrome.  
5.3 Alzheimer’s Disease and Acetylcarnitine: Potential role for 
CrAT in Neurodegenerative Disease.  
 
Alzheimer’s disease (AD), the most common form of dementia, is 
projected to affect 66 million people by 2030 and a staggering 115 million by 
2050 (Alzheimer’s disease international consortium). AD is classified by the 
presence of neurofibrillary tangles (aggregates of the hyperphosphorylated tau 
protein), and amyloid β peptide plaques in the brain (Braak and Braak 2001). The 
need to find underlying mechanisms of disease is high, as the Medicare and 
Medicaid spending for AD patients was $130 billion in 2011 and continues to rise. 
Moreover, healthcare costs associated with AD patients are three and nine times 
higher than non-AD patients through Medicare and Medicaid, respectively 
(Bynum 2011).  
Two forms of AD exist, early onset (with primarily genetic risk factors), and 
late onset. Strikingly, late onset AD is prevalent in more than 50% of people over 
the age of 85. Genetic risk factors identified in early onset AD include mutations 
in three genes, amyloid-β protein precursor, and both presenilin 1 and 2 (Selkoe 
et al. 1997). Genetic studies have also identified risk alleles for late onset AD, 
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including disruptions in the APOE-ε4 allele. Mutations in APOE-ε4 lead to a three 
times increased risk of developing AD (Farrer et al. 1997). Importantly, the 
advent of genome wide association studies has identified nine additional risk 
genes (reviewed in Bettens et al. 2013), with more likely to come as next-
generation sequencing broadens the potential to probe for variants. Importantly, 
alternative lifestyle risk factors have been reported. These include age, lower 
education (Cummings 2004), and the metabolic syndrome (reviewed by 
Luchsinger and Gustafson 2009). Despite progressing work to delineate AD risk 
factors, the underlying mechanisms of disease are still largely unknown. 
Though drug treatments exist for cognitive and behavioral AD symptoms, 
there is no cure for the disease. One such intervention that has gained recent 
attention is acetylcarnitine supplementation. Acetylcarnitine has been shown to 
slow the progression of neurodegeneration and improve spatial learning, memory 
function and other cognitive and behavioral measurements (reviewed in Liu and 
Ames 2005 and Acetyl-L-carnitine, monograph 2010). Initially, acetylcarnitine 
was expected to act through choline acetyltransferase to combine acetyl-CoA 
with choline to produce the neurotransmitter, acetylcholine (Imperato et al. 1991, 
Dolew and Tucek 1981). However, studies showing the positive effects of 
acetylcarnitine on energy metabolism suggest a more sophisticated mechanism 
of action. We hypothesize that acetylcarnitine, the primary substrate of the 
reverse CrAT reaction, might be acting through neuronal CrAT to buffer 
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intramitochondrial acetyl-CoA in AD patients, thereby increasing energy 
metabolism and brain function. In support of this hypothesis, CrAT has been 
shown to be highly active in the brain (Bailey and Lahiri 2012), with over 90% 
greater activity compared to choline acetyltransferase (Kalaria et al. 1992). 
However, neuronal CrAT activity appears to diminish with age (Liu et al. 2002b). 
Moreover, patients with AD have further decreased CrAT activity in the frontal 
cortex, temporal cortex, hippocampus and cerebellum compared to age-matched 
control subjects (Kalaria et al. 1992), suggestive of a role for CrAT in AD.  
Though the mechanism underlying acetylcarnitine action is unknown, it 
has been suggested that one role of acetylcarnitine supplementation is to delay 
mitochondrial decay due to mitigation of oxidative damage (Butterfield et al. 
2002, Butterfield et al. 2002b, Hagen et al. 2002, Liu et al. 2002). 
Malondialdehyde (MDA), a product of lipid peroxidation, is significantly increased 
with age (Liu et al. 2002b), and is induced to a greater extent in Alzheimer’s 
disease compared to control subjects (Ozcankaya and Delibas 2002). Liu et al. 
(2002b) showed MDA functions to inhibit substrate binding to the CrAT enzyme. 
Importantly, acetylcarnitine supplementation restored neuronal CrAT activity and 
substrate binding. These data imply that the positive effects of acetylcarnitine 
might be due to activation of the CrAT reaction.   
Additional studies suggesting the potential use of acetylcarnitine as a 
neuronal fuel during starvation (Kuratsune et al. 1997, Yamaguti et al. 1996) may 
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point to another role for CrAT-mediated acetylcarnitine use in AD. Importantly, 
acetylcarnitine supplementation in aged rats resulted in decreased neuronal 
lactic acid coupled with increased phosphocreatine and ATP levels (Aurelit et al. 
1990), thereby suggesting a similar CrAT-mediated acetyl-CoA buffering 
mechanism as described in skeletal muscle in Chapter 4. Furthermore, 
diminished ATP levels in a neuronal AD cell line were rescued with 
acetylcarnitine supplementation (Dhitavat et al. 2002). We hypothesize that the 
critical role of acetylcarnitine in buffering acetyl-CoA and ATP is blunted by 
diminished CrAT activity in the aging brain and is further disrupted in patients 
with AD, contributing to neuronal derangements associated with disease. 
Therefore, the study of neuronal CrAT could prove fruitful for the treatment of AD. 
To definitively test the importance of CrAT in AD, studies using our tamoxifen-
inducible total body CrAT knock out mouse model could become useful. These 
studies in combination with acetylcarnitine supplementation in aging mice might 
enhance our understanding of acetylcarnitine supplementation and the 
pathogenesis of AD. 
5.4 Summary: 
In summary, we proposed the critical role of CrAT in acetyl-CoA 
regulation.  These studies demonstrated that alterations in this metabolite pool 
are detrimental to mitochondrial homeostasis. Summarized herein, these findings 
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additionally suggest the potential role of CrAT in mitochondrial stress and 
neuronal nutrient homeostasis.  
Data herein demonstrated an inhibitory role of long chain acyl-CoAs on 
forward flux through the CrAT reaction. Lipid stress may persistently compromise 
CrAT activity in obesity and diabetes, leading to a potentially harmful 
accumulation of acetyl-CoA which contributes to derangements in metabolic 
flexibility. In support of this hypothesis, muscle specific CrAT deficiency resulted 
in glucose intolerance and a metabolically inflexible state (Muoio et al. 2012). 
These data suggest that a small molecule inhibitor of the long chain acyl-CoA 
binding site on CrAT may be a useful treatment for insulin resistance. This 
treatment would allow increased flux through the CrAT reaction and normalized 
glucose homeostasis. Because incidence of diagnosed cases of type II diabetes 
have nearly doubled in the past decade, (CDC 2010), treatment options that 
normalize glucose homeostasis before progression to full-blown type II diabetes 
are critical.  
 Alternatively, Chapter 4 summarized the role of CrAT in buffering 
acetyl-CoA during exercise. These studies demonstrated the role of CrAT-
mediated acetyl-CoA maintenance in fatigue. We hypothesize that CrAT 
functions to sustain high rates of mitochondrial ATP production in two ways.  
First, contraction-induced recycling and/or import of acetylcarnitine could supply 
a readily available source of acetyl group donors to buffer transient deficits in 
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rates of glucose, amino acid and fatty acid catabolism.  Secondly, CrAT permits 
rapid and efficient trafficking of acetyl groups from production to the TCA cycle.  
By residing in close proximity to the various enzymatic sources of acetyl-CoA 
(e.g. PDH and ketothiolase), CrAT might alleviate kinetic hindrances due to 
product inhibition.  Additionally, similar to creatine kinase, which uses PCr for the 
trafficking of ATP from its production site to the myofibrils during work, we 
hypothesize that cycling through the CrAT reaction could be critical to overcome 
the thermodynamic inefficiencies of diffusional flux. These studies could provide 
therapeutic insights into patients suffering from muscle weakness and fatigue, 
commonly seen with inborn errors of mitochondrial metabolism, peripheral 
vascular disease and cardiometabolic disease.  
In aggregate, these data highlight the importance of acetyl-CoA buffering 
for the maintenance of PDH activity and glucose disposal. We suggest that lipid-
induced regulation of the CrAT enzyme promotes the transition from feeding to 
fasting. However, this mechanism seems counterintuitive during exercise, when 
long chain acyl-CoA concentration is high (Thyfault et al. 2010) but flux through 
the CrAT reaction is critical. Similarly, palmitoylation has been shown to inhibit 
multiple enzymes in glycolysis during the fed to fasted transition, whereas this 
regulation would become detrimental during exercise (Yang et al. 2005, Jenkins 
et al. 2011). One possible explanation is that during exercise, enzyme substrates 
overwhelm the CrAT reaction, overriding any inhibition by long chain acyl-CoA. 
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This scenario does not seem likely because palmitoyl-CoA acts as a mixed-
model inhibitor of CrAT. The term “mixed” refers to the combination of 
uncompetitive inhibition, where the inhibitor can bind only to the enzyme-
substrate complex and competitive inhibition, where the inhibitor can bind to the 
enzyme only in the absence of substrate. Therefore, palmitoyl-CoA-mediated 
inhibition affects the CrAT reaction regardless of short chain acyl-CoA 
abundance. Rather, we suggest the possibility that rapid turnover of the long 
chain acyl-CoA pool during exercise might prevent CrAT inhibition. Immediate 
utilization of the long chain acyl-CoA pool reduces the likelihood that excess 
palmitoyl-CoA might accumulate and inhibit CrAT. Likewise, rapid turnover of 
long chain acyl-CoAs would prevent accumulation of the palmitoyl-CoA 
necessary for the palmitoylation and inhibition of enzymes in glycolysis. 
Therefore, we propose the importance of fatty acid turnover in the regulation of 
CrAT activity. This hypothesis would suggest a fatty acid-mediated inhibition of 
CrAT at rest but not during exercise.  
However, data herein demonstrate a persistent inhibition of the CrAT 
enzyme in obese and diabetic rodents. These derangements in CrAT activity 
could lead to exercise intolerance. Indeed, aging and chronic disease are often 
accompanied by muscle weakness and fatigue. These patients could be 
experiencing chronic lipid-induced CrAT insufficiency, contributing to exercise 
intolerance. Because exercise promotes metabolic health and mitigates a wide 
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range of medical conditions, stimulation of the CrAT reaction in these patients 
could delay fatigue and promote exercise capacity. However, more work is 
needed to fully understand this mechanism. 
Though the current document discusses multiple novel aspects of the 
CrAT enzyme activity, more work is needed to fully elucidate its action. We 
propose this enzyme could have an important role in mitigating reactive oxygen 
species production and hyperacetylation. Additionally, we believe CrAT could 
play a role in degenerative disorders, such as Alzheimer’s disease in the brain. 
Though the answer to these and a number of other intriguing questions await 
further investigation, data herein provide a better understanding of CrAT action 
and suggests multiple paths of therapeutic intervention. 
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